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Abstract 
 
Introduction: Cancer of the same origin show considerable heterogeneity in sensitivity 
to chemotherapy both clinically and in vitro, and show rapid adaptation to 
chemotherapy based on gene expression. This study tested the hypothesis that anti-
cancer drug exposure could render tumour-derived cells more susceptible to second 
agents, particularly those with specific molecular targets in survival pathways and with 
the knowledge of cellular pathways, determine new more effective molecularly 
designed regimens. 
 
Materials and Methods: Single agent, combinational and sequential chemosensitivity 
of a series of cell lines and tumours was assessed using the ATP-based tumour 
chemosensitivity assay (ATP-TCA). Sensitivity data was correlated with gene 
expression, measured by quantitative reverse-transcriptase polymerase chain reaction 
(qRT-PCR) in a TaqMan Array following extraction of mRNA from cell samples and 
standardisation to the housekeeping gene (PBGD). Mutation analysis kits utilising 
Amplification Refractory Mutation System (ARMS) and scorpion technology were used 
to establish the presence of activating mutations in EGFR, KRAS, BRAF and PI3K. 
 
Results: Heterogeneity in cellular sensitivity to cytotoxic and targeted agents was 
observed. While gene expression was seen to show some correlation with sensitivity to 
signalling pathway combination targets, the complexity associated with cellular 
adaptation prevented the prediction of response to second agent sequential 
treatment. 
 
Discussion: This study has identified potential novel combinations for use in ovarian 
cancer. This combination of EGFR and PI3K inhibitors has shown greater sensitivity in 
cell based assays compared with single agent activity and could become the focus of 
future clinical trials. Successful application of 384 well ATP-based chemosensitivity 
assays has shown to be a valuable tool for future cell based research. The quantity of 
viable tumour derived cellular material is diminishing; therefore, methods developed 
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here will continue to provide the means to complete these types of studies in the 
future.  
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Chapter 1 -  Introduction
 1.1 Hypothesis and Aims 
 
We suggest that it is possible to drive neoplastic cells to adapt to low doses of anti-
cancer treatment that will render them more susceptible to a second dose or course of 
anti-cancer treatment. 
 
1. To determine whether anti-cancer drug exposure can render tumour-derived cells 
more susceptible to second agents, particularly those with specific molecular targets in 
survival pathways. 
 
2. To use knowledge of cellular pathways to determine new more effective molecularly 
designed regimens. 
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1.2 Cancer Hallmarks and Tumour Biology 
It has been over a decade since the seminal paper by Hanahan and Weinberg was 
published in the year 2000 outlining the hallmarks of cancer (1). They believed then; 
that a small number of underlying principles could explain the entirety of the cancer 
formation process. These six fundamental principles included; self-sufficiency in 
growth signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of 
programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis (1). Since its publication a vast 
amount of knowledge has been learned about why cells grow uncontrollably and the 
paper has recently been revised to include further hallmarks (2).  
 
Figure 1:  Hallmarks of cancer (2) 
Unfortunately, the amount of knowledge learned is not necessarily proportional to its 
use in successful therapeutics. This comparison will not however remain unbalanced, 
advances in diagnostics, greater use of molecularly targeted treatments, individualised 
therapies and more effective maintenance treatments are beginning to appear. With 
the inclusion of four new hallmarks by Hanahan et al in 2011 (Figure 1) to include 
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deregulation of energy supplies, immune system evasion, genetic instability/mutation 
and inflammation (encompassing the effect cancer cells have on their surrounding 
environment), the ability to exploit treatments targeting combinations of these ten 
cancer hallmarks is now present and could lead to real benefits for patients (2).  
 
Examples of how these 10 hallmarks of cancer are related to molecular mechanisms 
and cancer treatment are examined below.  
1.2.1 Evading Growth Suppressors 
Antigrowth signals have the ability to block proliferation and maintain quiescence and 
homeostasis in normal cells. For cancer cells to flourish they must evade these anti-
proliferative signals. This can be achieved via cell cycle deregulation or entering 
irreversibly into postmitotic differentiated states. 
 
The replication of normal cells is a highly regulated and accurate process. From the 
standpoint of chromosomes, there are four phases constituting the cell cycle. These 
comprise of DNA synthesis (S) and mitosis (M) which alternate with one another, 
separated by two "gap" phases (G2 and G1) required for preparation and growth. 
During the S phase DNA synthesis/replication occurs providing two sister chromatids 
(joined at the centromere) resulting in the existence of duplicated genetic material 
within the cell, ready to be divided into two daughter cells. The G2 phase follows 
successful completion of the S phase in which the cell prepares for mitosis. Both 
mitosis and cytokinesis define the M phase of the cell cycle. This stage can be further 
sub-divided to include: prophase; prometaphase; metaphase; anaphase; telophase and 
cytokinesis. The result is nuclear division and the production of two daughter cells that 
are genetically identical to each other. The G1 phase follows cytokinesis and is where 
cells increase in size, produce RNA and synthesise proteins. Cells may pause within this 
phase and become quiescent entering a temporary resting period (G0). These then 
require stimulation by growth factors before entering back into the cell cycle. Moving 
through these phases is mediated carefully with safeguards and checkpoints in place to 
ensure DNA is intact and that the cell is functioning normally. Deregulation of the cell 
cycle occurs when these checkpoints are disrupted which can lead to malignancy. 
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These cell cycle check points are mediated by cyclins and cyclin dependent kinases 
(CDKs) (3).  The pattern of cyclin expression varies throughout the different phases 
defining the relative position of a cell within the cycle. The level of CDK’s within a cell is 
fairly stable; each must bind their appropriate cyclin in order to be activated. Once 
these complexes form, they have the ability to add phosphate groups to a variety of 
protein substrates, which in turn control processes in the cell cycle (4). Cell cycle 
inhibitors halt the progression of the cell through the cycle and are instrumental in 
prevention of tumour formation. Oncogenes such as c-myc also have the ability to 
activate or repress target genes involved in cell-cycle progression (5). C-myc has been 
shown to be amplified in various cancers and its deregulation linked to increases in 
cyclin A and cyclin E expression which are required for the transition of cells from G1 to 
S phase (6). 
1.2.2 Sustaining Proliferative Signalling 
Normal cells do not have the ability to actively proliferate without stimulation via 
growth signals. Cancers manage to circumvent this stimulatory dependence in many 
ways including; mutation of oncogenes, structural alteration of regulatory proteins 
such as AKT or Ras, deregulation of cellular receptors and autocrine growth factor 
stimulation. 
 
AKT finds itself at the centre of a diverse signalling cascade involved in many pathways, 
one of which can result in continued proliferative signalling (Figure 2). This abnormal 
activation has being widely implicated in many cancers (7). Elevated AKT activation can 
result from a number of points within its signalling pathway. An example of enhanced 
AKT activation can be due to altered phosphatidylinosital-3 kinase (PI3K) activation 
resulting from; mutations (8) or amplification of growth factor receptors (such as ErbB 
family members) (9), RAS oncogenes (10), or PI3K itself. Overexpression and mutations 
of AKT itself can also contribute to the elevated expression in human cancers (11). Loss 
of function mutations as well as decreased expression of the 3'-phosphatase with 
tensin homology (PTEN) which shuts off PI3K signalling may also contribute to 
continual activation of AKT resulting in continued proliferative signalling (12, 13).  
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Figure 2: Simplified AKT signalling cascade 
1.2.3 Resisting Cell Death 
Proliferation is not the only means by which cancer cells can expand their numbers. 
Acquiring the ability to avoid programmed cell death (apoptosis) is also a major 
contributory factor. Avoidance of apoptosis can occur through several processes, of 
which loss of function or mutations involving tumour suppressor genes (e.g. p53) are 
frequently found in many tumours (14).  
 
Apoptosis is controlled by an array of cell signals involved in an energy-dependent 
cascade of molecular events. These either originate intrinsically (mitochondrial 
pathway) or extrinsically (death receptor pathway) (15). In many cancers proapoptotic 
signalling components are shown to be downregulated or lost (Bax, Bak, Bid, Bim) 
while antiapoptotic components can be found to be upregulated (Bcl-2, Bcl-XL, Bcl-W) 
(14). 
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1.2.4 Enabling Replicative Immortality 
Normal cells have a finite replicative potential, progressing through a definitive 
number of doublings before senescence. This replication limit is known as the Hayflick 
limit (16). For cells to develop into large tumours they at some point must breach this 
barrier and acquire unlimited replicative potential.  
 
The ability of tumour cells to maintain telomeric DNA underlies their ability to possess 
unlimited replicative potential (17). Telomeres form a protective region of repetitive 
nucleotide sequences at each end of a chromosome. They are vulnerable to 
dysfunction due to their progressive shortening during each round of DNA replication. 
It has been shown that in advanced cancers, telomerase (the enzyme which adds DNA 
sequence repeats to the end of DNA strands) is reactivated serving to maintain 
telomere length and directly regulate cancer-promoting pathways (18). 
1.2.5 Inducing Angiogenesis  
Like normal cells tumour cells require the delivery of nutrients and oxygen and the 
ability to remove metabolic waste and carbon dioxide. These requirements are met by 
the development of a tumour neovasculature environment.  The continued sprouting 
of these new vessels (angiogenesis) help sustain the expanding neoplastic growth of 
malignant tumours (19). These angiogenic regulators are often disrupted in tumour 
cells leading to possibilities of anti-angiogenic targeted therapy (20-24).  
 
As an example of successful treatment targeting a hallmark of cancer bevacizumab 
(Avastin), an inhibitor of vascular endothelial growth factor (VEGF), was approved by 
the FDA in 2004 for the treatment of metastatic colorectal cancer.  This monoclonal 
antibody binds to human VEGF (angiogenesis inducer) preventing it from binding to 
endothelial surface receptors lining blood vessel walls, thus preventing formation and 
growth of new blood vessels (25).  
1.2.6 Activating Invasion and Metastasis   
Tumour metastasis involves a succession of changes resulting in the development of 
distinct macroscopic tumours in another non-adjacent organ via transportation in the 
bloodstream or the lymphatic system. This is achieved when malignant cells break 
8 
 
away from the primary tumour by the degradation of the extracellular matrix (ECM) by 
matrix metalloproteinases (MMP’s). This family of zinc-dependent enzymes coordinate 
the breakdown of extracellular matrix and have been shown to be expressed by both 
tumour and stromal cells (26). 
 
The loss of E-cadherin in many human carcinomas provides strong support for its role 
as a key suppressor of metastasis (27-29). E-cadherin is a key cell-cell adhesion 
molecule forming adherens junctions with adjacent epithelial cells, giving sheet like 
structures. 
 
In ovarian cancer, E-cadherin expression in cells found floating in ascites and at 
metastatic sites is lower than in the primary tumour (30). Although this process is still 
not fully understood, cells with low E-cadherin expression have been found to be more 
invasive, while its absence predicts poor patient survival (31-36).  
1.2.7 Deregulating Cellular Energetics  
Cancer cells have been shown to have an altered glucose metabolism (37). These cells 
develop the ability to adjust their metabolism in order to support their need for rapid 
proliferation (38-40). Studies have shown that several oncogenic and tumour 
suppressors can directly activate hypoxia-inducible factor 1 (HIF-1) which directly 
controls the transcription of glycolysis enzymes required for cancer cell progression 
and metastasis (41, 42).  
1.2.8 Avoiding Immune Destruction 
Throughout the last few decades several hypotheses on cancer cell immune evasion 
have been suggested. The most recent concept is that of immunoediting (43-45). If 
cancer cells survive immune elimination they are able to enter an equilibrium phase. 
The immune system exerts a selective pressure on the unstable tumour cells leading to 
the acquisition of immunosuppressive characteristics (such as cytokine secretion and 
Fas-L expression constructive to lymphocyte death). This immune evasion helps 
promote tumour growth and metastasis (46).   
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1.2.9 Genome Instability and Mutation 
Genomic instability is a characteristic of almost all human cancers. These consist 
mainly from, chromosomal instability (CIN), microsatellite instability (MSI) and 
karyotypic instability associated with loss of telomeric DNA (18, 47). Chromosomal 
instability is associated with poor prognosis in solid tumours (48). It can be 
characterised by abnormal chromosome structures and numbers as well as abnormal 
mitoses. Microsatellite instability is caused by defects in the normal DNA repair 
process leading to unchecked damaged DNA. The sections of DNA known as 
microsatellites consist of a sequence of repeating units which can lengthen or shorten 
and become unstable. 
1.2.10 Tumour Promoting Inflammation  
In healthy tissues, inflammation is associated with the innate immune system whose 
functions include wound healing, fighting infections and cellular/tissue repair. The 
inflammatory process can contribute to the tumour micro-environment by producing 
chemicals such as growth/survival factors and matrix modification enzymes. 
Inflammatory cells can also promote tumour formation by the release of mutagenic 
chemicals such as reactive oxygen species (ROS) (2). 
 
With the mass of knowledge regarding cancer hallmarks and their effects on neoplastic 
development expands, this ensures the continued enrichment of understanding 
required for the continued development into effective treatments. 
1.3 Cancer Treatment and Therapy 
The treatment of cancer is variable and is dependent on numerous factors including 
the type, location and mass of the tumour as well as the stage of disease and general 
health of the patient. Designing successful treatment regimes relies on a multifaceted 
approach to directly remove or kill the cancer cells through surgery, radiation, 
chemotherapy, hormonal treatments, targeted therapy, antibodies or vaccines. 
 
Our modern-day use of chemotherapy in cancer therapy has its origins on the 
battlefields of the First World War. However, it wasn’t until the mid 1940’s that agents 
such as methotrexate were becoming more commonly used to treat child hood 
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leukaemia (49, 50). Although success has been achieved with new molecular targeted 
treatments, many cancer regimens still rely on older cytotoxic based drugs such as 
cisplatin for their foundation. 
1.3.1 Platinum Anti-tumour Compounds 
Platinum-based antineoplastic drugs still serve as one of the most important 
anticancer drug families used clinically. These agents are able to bind to and cause 
crosslinking of DNA which can result in inhibition of DNA repair and/or DNA synthesis 
in cancer cells ultimately triggering apoptosis. 
 
Defects in DNA repair mechanisms caused by mutations in BRCA1 and BRCA2 have 
been shown to render tumour cells more sensitive to inter-strand DNA crosslinking 
agents such as cisplatin and carboplatin (51, 52). This could suggest a potential marker 
of platinum sensitivity in BRCA1/2 deregulated tumours. 
 
Platinum resistance continues to be a major hurdle in cancer chemotherapy. Cisplatin 
sensitivity is not only regulated by its uptake, efflux or interaction with its target DNA, 
signalling responses to cisplatin-induced DNA damage may play a major role in the 
cancer cells fate (53). Due to renal and neurotoxicities associated with cisplatin, 
intensive efforts were made to devise analogues with fewer of these toxicities. This 
work led to the development of carboplatin, which produces primarily haematopoietic 
toxicity and appears to have an anti-tumour effect similar to cisplatin, previously 
shown in vitro to be equimolar (Cree IA, personal communication).  
 
Cisplatin enters the cells either passively by diffusion or mediated by a carrier such as 
copper. Cellular efflux is by the ATP-dependent transporters, ATP7A and ATP7B. 
Cisplatin is a complex of platinum which forms strong chemical bonds with cellular 
thiols, such as glutathione and metallothionein. On interaction with DNA, cisplatin 
stalls cell proliferation by inhibiting DNA synthesis, followed by the activation of DNA 
damage responses. The resulting cisplatin-DNA adducts are then repaired via the 
nucleotide excision repair system, inducing cell-cycle arrest (via p53 and c-Abl). 
Damage induced p53 activation leads to the induction of p21, GADD45, proapoptotic 
PUMAα, caspase-6, caspase-7, microRNAs (miR-34a) and promotes apoptosis by 
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binding and inhibiting the antiapoptotic Bcl-xL. Apoptosis may also occur via activation 
of the mismatch repair system, leading to the activation of JNK and p38 MAPK and 
stabilization of p73. The kinases (PKC, ERK, and AKT) are also involved in the regulation 
of cisplatin-induced cell death.  
 
A number of mechanisms of cellular resistance to platinum compounds have been 
identified (54). These mechanisms include decreased uptake/ increased efflux of the 
platinum compound, inactivation of the drug by cellular thiol compounds, enhanced 
repair of the platinum-related DNA damage, the absence of mismatch repair, and 
genotoxic induced stress activating multiple signal transduction pathways. MicroRNAs 
(miR-214) can also promote cisplatin resistance by down regulating PTEN and 
activating AKT (55). 
 
It has been suggested that the mismatch repair system plays a vital role in the 
cytotoxicity of cisplatin as these proteins recognise the cisplatin cross-links. Mispairing 
caused by these cross-links triggers the mismatch repair (MMR) pathway.  This 
produces a cycle of ineffective DNA repair. The repetitive cycles of MMR leads to 
growth arrest, accumulation of p53 and induction of apoptosis. However, in cells that 
are MMR deficient, the mispairs are not removed and apoptosis is not induced 
rendering the cells resistant to platinum as the cell continues to synthesise DNA 
containing mutations (56). 
1.4 Drug Resistance Mechanisms 
Despite a new era of molecular characterization of disease and the discovery of novel 
targets for drug development, cancer mortality rates have seen little change. The 
inevitable development of resistance to each new pharmaceutical entity continues to 
form an obstacle to successful drug treatment in cancer.  
 
1.4.1 Drug Pumps 
The overexpression of drug transporters has long been considered the predominant 
mechanism responsible for multidrug resistance (MDR), with increased expression of 
12 
 
members of the ATP binding cassette (ABC) transporter family playing a key role in this 
resistance.  
 
Of the 48 ABC transporters there are at least 12 which function as drug efflux pumps. 
These allow efflux of an assortment of substrates including ions, sugars, amino acids, 
lipids, toxins and anticancer drugs. The most widely categorised of the ABC 
transporters are ABCB1 (also known as MDR1 or P-glycoprotein), ABCC1 (also known 
as MRP1) and ABCG2 (also known as BCRP) (57, 58).  
 
MDR1 is an ATP-dependent efflux pump with broad specificity for anticancer drugs 
including vinca alkaloids, anthracyclines, epipodophyllotoxins and taxanes but not 
platinum compounds. These classes of transporters have long been associated with a 
decrease in anticancer drug accumulation in those cells exhibiting multidrug 
resistance. The inhibition of ABC transporter-mediated drug efflux has been a target 
for possible cellular resensitisation to chemotherapeutic agents (59). 
 
It has been shown that many cells with an acquired resistance to cisplatin often exhibit 
reduced drug accumulation. It is generally believed that reduced cisplatin 
accumulation in platinum resistant cells is due to a decrease in uptake rather than 
increase efflux as seen in other forms of drug resistance (53). 
1.4.2 Mutations 
Signalling pathways downstream of EGFR include the Ras/MAPK, PI3K/AKT and STAT 
pathways (60). Constitutive activation of these pathways through mutation uncouples 
downstream signalling from upstream receptor inhibition (61). Normally, binding of 
GTP to Ras is transient, and following activation RAS triggers a diversity of intracellular 
signalling before returning to its inactive state. Mutations in codons 12 or 13 of KRAS 
result in RAS mutants which are insensitive to RAS-GTPase activating proteins, while 
mutations in codon 61 inhibit the intrinsic GTPase activity of KRAS (62). The 
consequence of these mutations results in a failure to convert active RAS-bound GTP 
into its inactive form GDP. This allows constitutive activation of downstream signalling, 
independent of stimulation (63). KRAS mutations are found to be present in 
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approximately 40% of patients and have become biomarkers to predict for intrinsic 
resistance to EGFR-targeted agents (64-66). 
 
Activating mutations in BRAF affect downstream signalling through MAPK and appear 
to occur in a mutually exclusive manner with KRAS mutations (67). Although occurring 
less frequently BRAF mutations also appear to have intrinsic resistance to EGFR 
inhibitors (68, 69). Mutations in BRAF (V600E) may give rise to the subset of wild-type 
KRAS (wtKRAS) patients who do not respond to EGFR-targeted agents (68, 70). 
1.4.3 Development of New Signalling Pathways 
Many of the targets downstream of receptor tyrosine kinases can be trans-activated 
via a multitude of signalling cascades. The inherent feedback mechanisms associated 
with specific targeted treatment can lead to intrinsic resistance of these inhibitors. 
Sirolimus (Rapamycin) has been shown to have therapeutic activity in a variety of 
tumours; however, feedback mechanisms through the AKT/PI3K or MEK/ERK pathways 
can result in considerably reduced effects (71-73). 
 
Evidence suggests that despite tumour cells having adopted dominant growth factor 
pathways, they are not necessarily incapable of responding to other growth factors 
that may be present. The ability to switch to alternative growth signalling pathways 
during drug treatment represents an apparent means of limiting the actions of these 
highly targeted therapies.  Therefore, although EGFR inhibition may efficiently reduce 
EGFR signalling, IGFs acting through the IGF-1R can readily reactivate downstream 
signalling molecules and thereby re-establish tumour cell growth (74). 
 
In a percentage of gefitinib-relapsed patients affected by NSCLC, resistance occurs due 
to the amplification of the MET gene encoding for the receptor tyrosine kinase for 
hepatocyte growth factor (75, 76). The overexpression of MET and its interaction with 
other ErbB family members, mainly HER3, continues the downstream activation of 
signalling pathways in the presence of EGFR inhibition (77). It has been shown that in 
these instances inhibition of MET can restore sensitivity to EGFR inhibitors (75, 76). 
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1.5 Molecular Mechanisms for Sequential Therapy 
1.5.1 Sequential Therapy 
Sequential chemotherapy consists of the administration of non-cross resistant 
chemotherapy in a predetermined order for a defined number of cycles. Regimens are 
designed so that one anti-cancer agent is used before switching to an alternate anti-
cancer agent. This can help eliminate cells which have developed resistance to the 
primary agent. Mechanisms involved in resistance to chemotherapy usually involve up-
regulation of resistance mechanisms, or down-regulation of target genes. This 
adaptation has been shown to occur within hours of drug exposure (78).  
 
A cross-over effect has been observed within some clinical trials, in which patients 
treated with one type of chemotherapy show sensitivity to an alternative regimen 
following failure of the treatment to which they were first allocated (79). In these 
instances the mechanisms involved could specify a basis for sequential administration.  
1.5.2 Log Cell Kill 
As far as cancer chemotherapy has come, its practice still adheres to the concept of 
logarithmic cell kill (80). This concept indicates that a constant fraction of tumour cells 
will be killed by per cycle of drug dosing, regardless of initial body burden (81, 82). 
 
In single agent therapy the exponential growth in tumour cell number can be disrupted 
by one or more cycles of treatment, although the corresponding drop in the log 
number of cells is unlikely to be effective for long. The graphical response after each 
treatment shows an expected reduction of cell number to the right of which the cell 
number resumes at its previous growth rate (Figure 3).       
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Figure 3: The effect of treatment on logarithmic cell kill (83).                          
1.5.3 Design of Sequential Regimens  
The interval between cycles of chemotherapy has generally been the minimum time 
required to recover from drug toxicity (84). However, with increased observation of 
drug resistance mechanisms this time scale may not be appropriate. Where drug 
resistance is partially reversible or the mechanism by which resistance occurs is 
targetable a more molecular approach to sequential therapy may be more 
advantageous.  
 
The idea of sequential chemotherapy is to maintain dose intensity and preclude any 
cumulative toxicity by increasing drug diversity by reducing drug cross-reactivity. 
 
The late 1970’s- early 1980’s saw the impact of the design of new chemotherapy 
regimens using mathematical modelling. One such model ‘the worst drug rule’ states 
that if two non-cross-resistant drugs are used intermittently in treatment, then the 
drug with the weaker killing rate has to be applied first and/or for a longer period of 
time. This would ensure that the most effective drug would then kill the remaining 
fractions of the more resistant tumour cells (85). 
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Ciardiello et al believe that chemotherapy should be administered prior to targeted 
receptor inhibition (86). The reasoning behind this sequence comes from the situation 
in which the receptor inhibitor exerts its potential synergy with chemotherapy. The 
chemotherapy is inducing or has induced maximal cell damage; therefore the 
subsequent receptor blockade could interfere with the repair of this cell damage (86).  
 
Based on Di Nicolantonio et al, and Mercer et al, a successful molecular based 
sequential regimen would include a primary chemotherapeutic agent followed in close 
succession by a specific inhibitor against a target upregulated in response to the 
primary treatment (78, 87). This would require identification of specific stress 
responses in a population of heterogenic cancer cells, and would have to consider dose 
and time of administration.  
 
Recovery from dormancy status or recovery of proliferation provides an additional 
rationale for delay of additional courses of chemotherapy, particularly in slow growing 
solid tumours. 
         
Synchronizing cells with drugs that inhibit DNA synthesis or arrest cells in mitosis can 
be exploited with agents that specifically target the cell cycle. This process however, 
may also synchronize non-neoplastic target cells providing little improvement in the 
overall therapeutic effect. This effect can be shown to be beneficial in hormone-
dependent tumours. Hormones have been shown to manipulate metastatic breast 
cancer cells, where cells were arrested cytokinetically with tamoxifen and then pulse-
stimulated into the cycle with oestrogen. Chemotherapy can then be delivered at the 
time of maximum synchronization allowing for a greater portion of cell kill (84). 
1.6 Molecular Targeted Therapy and Individualised Treatments 
It could be said that there are as many types of cancers as there are people. Everyone 
is genetically different and so no two cancers are exactly alike. Recent studies have 
shown that differences in some small molecule targeted drugs can be explained by the 
absence or inclusion of specific mutations in related genes. This has inevitably initiated 
the rationale for molecular diagnostic testing for clinical decisions regarding 
chemotherapy administration. 
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The first molecular target used to aid cancer therapy was the receptor for the female 
sex hormone oestrogen which is required by many breast cancers for growth. Drugs 
selected for this target include tamoxifen which is a potent oestrogen receptor (ER) 
antagonist and newer drugs such as the aromatase inhibitors (88, 89).  
 
The expression of HER2 is associated with poor prognosis in many cancers. In those 
with breast cancer, treatment with the anti-HER2 antibody trastuzumab (herceptin) as 
a monotherapy or combined with regular chemotherapy may be beneficial. HER2, ER 
and progesterone receptors (PR) are routinely tested for expression via 
immunohistological staining, which helps aid chemotherapeutic regimen choice. HER2 
expression is driven by gene amplification, which is assessed by fluorescence in situ 
hybridisation (FISH) (90).   
 
Treatment with small molecule inhibitors of EGFR have shown to benefit non small cell 
lung cancer (NSCLC) patients that carry certain somatic mutations in their EGFR gene. 
There is also emerging evidence that mutations in KRAS may be predictive of a lack of 
sensitivity to either gefitinib or erlotinib in these lung tumours (91). It has been shown 
that mutations in EGFR, KRAS, BRAF and HER2 are frequently mutually exclusive in lung 
adenocarcinomas. This represents alternate pathways with which these tumours could 
continue to activate downstream pathways such as PI3K/AKT and MAPK (92). 
 
Antibody therapies directed against EGFR (cetuximab) have been shown to be clinically 
effective in a subset of colorectal cancer patients with a wild-type KRAS gene. In the 
UK at present, patients with metastatic colorectal cancer are tested for KRAS 
mutations prior to administration of EGFR antibody therapy. The presence of 
mutations in BRAF and PIK3CA genes found in those tumours which do not respond to 
anti-EGFR treatment suggests the need for further genotyping for these genes among 
KRAS wild-type tumours when being considered anti-EGFR therapies (65, 68).  
 
It is fast approaching a time where a single gene strategy for individualised treatment 
will become inadequate. The genetic roots of cancers are proving to be more 
complicated than current testing provides. Many tumours have a variety of mutations 
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thought to be important to chemosensitivity, as well as mutations within the same 
signalling pathways being found to occur in many tumour types. With greater 
knowledge of the correlation of these mutations with sensitivity to chemotherapy new 
targeted agents will be developed with tailored individualised tests for their detection. 
 
A number of studies have applied next-generation sequencing technologies to 
sequence cancer genomes to find mutations in other genes which may be targeted 
successfully (93, 94). Although effective, this type of approach (whole genome 
sequencing) is still cost prohibitive for current widespread diagnostic applications. A 
possible alternative to this costly methodology is exome sequencing. This method 
captures and sequences only in the coding exons (exomes) within the genome. With 
the popularity of this technique increasing, many cancer based exome studies are 
underway (95-99).  
1.7 EGFR Pathway in Cancer Treatment 
The epidermal growth factor receptor (EGFR) is a member of the erbB family of 
receptor tyrosine kinase proteins. This family also includes HER2/neu (erbB2), HER3 
(erbB3), and HER4 (erbB4). These are type I transmembrane growth factor receptors 
that activate intracellular signalling pathways in response to extracellular signals. 
Phosphorylation of the tyrosine kinase domain followed by homo/hetero-dimerization 
between different receptors of the erbB family leads to protein activation; followed by 
activation of downstream signalling cascades (Figure 24, Page 84) ultimately resulting 
in cell growth, differentiation, metabolism, cell survival and angiogenesis. 
 
Several members of the protein tyrosine kinase family have been shown to be 
activated in cancer cells and can often be associated with a poor prognosis. EGFR 
overexpression can lead to inappropriate activation of signalling cascades, which can 
lead to uncontrolled cell proliferation via pathways such as the RAS/RAF/MEK/MAPK 
pathway. In NSCLC an increased EGFR copy number can be associated with improved 
survival, suggesting that increased expression of mutant and/or wild-type EGFR could 
determine response to tyrosine kinase inhibitors (TKI’s) such as gefitinib (100, 101). 
Studies have shown that factors, such as high expression levels of EGFR and other ErbB 
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family members, might constitutively activate AKT and sensitize cells to EGFR inhibitors 
(102, 103).  
 
Gefitinib (Iressa®, Astra Zeneca) is an orally active tyrosine kinase inhibitor (TKI) 
targeted to the ATP-binding domain of EGFR (HER1; erbB1). However, in the absence 
of mutation, the mechanism of drug sensitivity to gefitinib is not fully understood as 
activity does not always correlate with the level of EGFR expression by the tumour cell. 
Studies have shown there to be great heterogeneity in the degree of inhibition 
observed when tumours were tested against single agent gefitinib as well as in 
combinations with other agents (104).  
 
Erlotinib (Tarceva®, Roche) specifically targets the epidermal growth factor receptor 
binding reversibly to its ATP binding site. Like gefitinib the mechanism of erlotinib 
sensitivity in the absence of mutation is not fully understood.  
 
The discovery of the correlation between EGFR mutations and EGFR-targeting drugs in 
NSCLC has lead to a more evidence-based therapeutic strategy, where treatment is 
considered based on patients mutation status (105-110). Routine mutation analysis to 
determine drug sensitivity in these tumours prior to drug administration is becoming 
more common place for such drugs as erlotinib and gefitinib (111). This is beneficial 
not only financially as these drugs can be expensive, but also means patients will not 
be required to undergo ineffective or inappropriate treatment.    
 
Correlation between EGFR mutations and clinical outcome with specific TKI’s is not 
found in all tumour types (112). A phase II study in ovarian cancer identified no 
mutations in 20 patients who responded to gefitinib therapy (stabilization or partial 
response) (113).  It maybe that in some tumours other pathways such as the 
EGFR/ERK1/2 and AKT pathways have greater relevance for cell survival and 
proliferation (114, 115).   
 
After variable time on treatment, cancer cells can become resistant to EGFR inhibitors. 
The main source of this resistance is the development of the mutation T790M 
(substitution of threonine 790 with methionine). Threonine 790 has been shown to be 
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an important factor in determining inhibitor specificity in the ATP binding pocket as it 
located at the entrance to a hydrophobic pocket in the back of the ATP binding cleft. 
Therefore, the T790M mutation is thought to sterically block binding of TKIs such as 
gefitinib and erlotinib (116, 117).  
 
Another mechanism of acquired resistance to EGFR inhibitors can be demonstrated by 
continued activation of downstream signalling pathways (including PI3K). Some studies 
have suggested that if cancer cells can find a way to effectively activate PI3K 
independent of EGFR activity, it will become resistant to EGFR TKIs (118, 119). 
 
The PI3K/AKT signalling pathway is frequently deregulated in cancer (120, 121). 
Tyrosine kinase receptors (EGFR) bind PI3K, either directly or indirectly via adaptor 
molecules. These active kinases generate pip3 at the lipid membrane which in turn 
facilitates the phosphorylation of AKT. This allows AKT to transmit signals to many 
downstream substrates including mTOR, influencing a variety of key cellular functions 
such as cell growth, survival, proliferation and metabolism. The phosphatase PTEN 
dephosphorylates pip3 terminating PI3K signalling, acting as the pathways negative 
feedback loop. PTEN is a tumour suppressor and loss of PTEN function or mutation has 
been linked to more aggressive and resistant tumours (122, 123). The ability of PI3K to 
directly activate AKT has lead to its interest as a potential drug target (124, 125).  
 
Progress has begun on the identification and development of novel PI3K inhibitors (61, 
126). ZSTK474 (2-(2-difl uoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine) 
(LC Laboratories, Massachusetts USA) is an experimental PI3K inhibitor which has been 
shown to inhibit all four PI3K isoforms in an ATP-competitive manner and has been 
used in these studies (127).  
 
HER3 is unique among the ErbB family due to its lack of tyrosine kinase activity. Due to 
its inactivity, it is not a direct target of kinase inhibitors. It does however have six 
tyrosine phosphorylation sites which effectively couple the protein to the PI3K/AKT 
pathway via P85α when it is activated by dimerization with other HER molecules. 
Binding sites for PI3K (P85α) are also found in EGFR and HER4 but not HER2. It has 
been shown that EGFR-targeting drugs preferentially inhibit AKT phosphorylation in a 
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dose-dependent manner. This suggests that greater sensitivity to EGFR targeting drugs 
would be seen in HER2/HER3 and EGFR/HER3 heterodimers (114). It could therefore 
be considered that over expression of HER3 could also contribute to resistance to EGFR 
and HER2 inhibitors.  
1.8 Ras Pathway in Cancer Treatment 
Given the vital role of the Ras-Raf-MEK-ERK signalling pathway in cell proliferation and 
survival it is unsurprising that alterations in this pathway are highly prevalent in human 
cancer. 
 
Mutations in the KRAS gene have been shown to lead to a constitutively active 
ras protein which subsequently leads to increases in proliferation and malignant 
transformation (128). In colorectal cancer, treatment with the EGFR inhibitor 
cetuximab (Erbitux®) is not effective among patients with a mutated KRAS gene. KRAS 
mutation status in colorectal cancer is used as a clinical diagnostic tool to predict 
resistance to the anti-EGFR antibody, cetuximab (129-132).  KRAS mutations have also 
been shown in gynaecological tumours. However, their significance to pathway 
signalling is a much debated question (133-136). Examples of this are found in two 
studies where mutations in KRAS and BRAF were shown to correlate with 
overexpression of activated ERK1/2 in ovarian serous tumours (135), which is in 
contrast to findings in endometrial cancer where ERK activation occurs in a KRAS and 
BRAF independent manner (137). This discrepancy may suggest that the effect of KRAS 
mutations may be organ specific. 
 
Many effector pathways downstream of RAS are comprised of kinase cascades, which 
provide multiple pathway points for potential therapeutic intervention. Two such 
pathways, the RAF/MEK/ERK and PI3K pathways have shown promise for therapeutic 
targets (138-141). 
 
Studies have documented the hyperactivation of MEK1/MEK2 and ERK1/ERK2 in solid 
tumour malignancies (142). This activation has been shown to directly influence RAS 
pathway dynamics (143). The blockade of ERK1/2 by small molecule MEK1/2 inhibitors 
has shown a variety of anti-proliferative effects in various tumour cell models. Despite 
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a strong rationale for the use of MEK1/2 inhibitors in the treatment of cancer their 
effectiveness has yet to prove evaluable (142). It is likely that MEK1/2 inhibitors will 
find their therapeutic value with their use in combinations with either other targeted 
or conventional cytotoxic agents. This has already been seen with the combination of 
ERK1/2 and PI3K inhibitors producing synergistic effects on tumour regression (144). 
1.9 Mevalonate Pathway in Cancer Treatment 
The mevalonate pathway performs several key functions within cells including 
synthesis of cholesterol and the non-sterol isoprenoids farnesyl and geranylgeranyl 
pyrophosphate (FPP, GGPP). These are important in prenylation of small GTPase 
proteins such as RAS. The process of prenylation involves farnesylation and 
geranylgeranylation from the mevalonate metabolite farnesyl pyrophosphate (FPP) as 
shown in Figure 4.  
 
While farnesylation is usually required for the translocation of Ras to the cell 
membrane during its activation, NRAS and KRAS can be geranylgeranylated in the 
presence of farnesyl transferase inhibitors (FTIs). This gives rise to a possible 
explanation for the limited clinical efficacy of these agents (145-147). Ras signalling has 
shown to be involved in many cancers, as part of activated growth receptor signalling 
pathways (e.g. Raf/MEK/ERK) or activating mutations during carcinogenesis where 
mutations upstream and downstream of RAS can result in growth stimulatory effects 
(148). Therefore, inhibition of the mevalonate pathway could be used to treat cancers 
with multiple effects, including theoretical effects on the RAS pathway. 
 
Drugs that disrupt the mevalonate pathway already exist. 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) inhibitors such as the statins can reduce the entry of 
mevalonate into the pathway by inhibiting its synthesis from 3-hydroxy-3-
methylglutaryl coenzyme A (Figure 4). This blockade prevents the formation of 
downstream products, including cholesterol, farnesyl pyrophosphate (FPP), and 
geranylgeranyl pyrophosphate (GGPP).  
 
Inhibitors of farnesyl pyrophosphate synthase (FPPS) are also widely available. The 
nitrogen containing bisphosphonates such as zoledronic acid form a class of drugs 
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which are widely used for treatment of osteoporosis and bone disorders including 
tumour associated bone disease (149). The enzymatic blockade of FPPS by zoledronic 
acid results in the depletion of intermediate isoprenoids (FPP, GGPP), many of which 
are needed for post-translational protein prenylation (150).  
Figure 4: Mevalonate Pathway- N-bisophosphonates inhibit FPP-synthase, leading to 
accumulation of IPP, which generates ApppI from AMP. ApppI has been found to be 
toxic to cells (151), while statins inhibit HMG-CoA reductase. 
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In addition to the loss of protein prenylation brought on by FPPS inhibition, zoledronic 
acid has been shown to cause the accumulation of intra-cellular isopentenyl 
pyrophosphate (IPP). Subsequently this accumulation induces the biosynthesis of the 
pro-apoptotic ATP analog ApppI (1-adenosin-5’-yl ester 3-(3-methylbut-3-enyl) ester 
triphosphoric acid) which has been shown to interfere with mitochondrial function and 
induce apoptosis (151-155). Apoptosis brought about by ApppI is thought to occur 
through the blockade of mitochondrial ADP/ATP translocase (151).              
Prediction and Measurement of Response to Chemotherapy 
The need for rapid, reliable and accurate assessment of cell viability and proliferation 
is a prerequisite for all in vitro and in vivo studies employed to determine the effective 
drug response of solid tumours.  
 
Cell viability can be defined as the number of ‘healthy’ cells in a sample irrespective of 
whether the cells are actively dividing or are quiescent. The simplest way to test 
viability after a toxic agent is administered is to count the remaining live cells. This can 
be achieved by direct visualisation for morphological changes or by observed changes 
in membrane permeability inferred from the exclusion, uptake or retention of certain 
dyes.  
 
An alternative method to detect cell viability is to measure metabolic activity. Rather 
than relying on cell membrane integrity to determine viability these assays determine 
the ability of the cell to perform biochemical reactions resulting in detectable by-
products.  Methodologies for the detection of metabolic activities can include 
absorbance, fluorescence and luminescence.   
 
Assays that determine cell viability are useful for determining chemotherapeutic 
response as they can also detect non-rapidly dividing cells such as many primary solid 
tumours for which proliferation rate is relatively low (156).  
 
The measurement of cellular proliferation is defined by the number of cells that are 
actively dividing in a culture. Measuring cellular proliferation can be achieved via the 
use of clonogenic assays to determine the number of colonies produced from a single 
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cell in the presence of toxic agents. Proliferation can also be directly determined 
through the measurement of the incorporation of labelled precursors into DNA.  This 
measurement of DNA synthesis is proportional to the amount of cell division occurring 
within the assay culture. Cell proliferation can also be measured indirectly by 
observing molecules that regulate the cell cycle or by quantifying their amounts via 
Western blots, ELISA, or immunohistochemistry. 
1.9.1 Cell-Based Assays for the Detection of Cell Viability and Proliferation 
The prediction of tumour sensitivity to anticancer agents has been widely explored, 
generating a variety of methodologies by which to measure response to treatment. 
There is no gold standard test used by all to determine the response to cellular toxicity 
and many techniques are still currently employed, many of which are briefly outlined 
below. 
1.9.1.1  Spectrophotometric and Colorimetric Assays 
The lactate dehydrogenase assay measures either the number of cells via total 
cytoplasmic LDH or membrane integrity by the amount of cytoplasmic LDH released 
into the medium. Lactate dehydrogenase (LDH) is an enzyme which catalyzes the 
interconversion of pyruvate and lactate with concomitant interconversion of NADH 
and NAD+. These products supply energy to living cells (157). This assay is based on the 
reduction of NAD by LDH which is responsible for the stoichiometric conversion of a 
tetrazolium dye. This coloured compound can then be measured via a 
spectrophotometer. 
 
Many dyes can also be used to test viability by selectively colouring dead tissues or 
cells. This is based on the principle that live cells possess intact cell membranes and so 
will exclude certain dyes (trypan blue, eosin, or propidium) whereas dead cells will not. 
 
Trypan blue is a toluidine derivative. When this dye is mixed with a cell population, 
viability can be visually examined to determine whether cells have taken up or 
excluded the dye. A viable cell with an intact membrane will have a clear cytoplasm 
whereas a nonviable cell will have taken in the dye and will appear blue. 
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Detection of cell survival can be determined via dye inclusion methods. Neutral red (3-
amino-m-dimethylamino-2-methylphenazine hydrochloride) is a weak cationic 
supravital dye that has the ability to penetrate cell membranes by non-ionic diffusion 
and accumulate intracellularly in lysosomes (158). Cell survival can be measured via 
the quantification of the number of viable cells following drug exposure (159). 
 
The differential staining cytotoxicity (DiSC) assay can be used to test efficacy of drugs 
against tumour cells in vitro identifying optimal therapy. Tumour cells are placed in 
culture and treated with drugs of interest from between 4-6 days. Cells are then 
stained within the culture plate with fast green dye before removal to slides and 
counterstaining with haematoxylin and eosin (H&E). A live cell with an intact 
membrane precludes staining with the green dye. Therefore, drug sensitivity can be 
measured by calculating the ratio of live cells in the drug treated samples to the 
number of live cells in the untreated controls (160). 
 
Long term effects of cytotoxic and cytostatic drugs can be evaluated via the use of 
clonogenic assays. These can measure the proliferative ability of single cells to grow 
and produce viable colonies over a period of weeks (161). After this time viable 
colonies can be fixed and stained before being counted on a stereomicroscope or via 
image analysis. By comparing the number of colonies in a drug exposed plate with drug 
free control plates drug sensitivity or resistance can be determined.  
 
The MTT, MTS, XTT and WST are colorimetric assays based on the ability of living cells 
to convert tetrazolium salts into formazan crystals determining mitochondrial activity. 
The solubilised formazan reagent can then be measured spectrophotometrically. In 
most cell populations the total mitochondrial activity is related to the number of viable 
cells and so these assays can be used to measure the in vitro cytotoxic effects of drugs 
(162).  
 
The principle of the sulforhodamine B assay is to measure the total biomass of a 
cellular sample via staining of the cellular proteins with the Sulforhodamine B. The 
measurement of corresponding drug-induced cytotoxicity and cell proliferation is 
detected by the ability of the protein dye sulforhodamine B to bind electrostatically 
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and pH dependently on the protein basic amino acid residues of trichloroacetic acid-
fixed cells (163).  
The caspase-cascade system plays vital roles in the induction, transduction and 
amplification of intracellular apoptotic signals (164). Following drug exposure a 
caspase specific peptide conjugated to a colour reporter molecule (p-nitroaniline) is 
added to the cell lysate. Cleavage of the peptide by the caspase releases the 
chromophore, which can be quantified spectrophotometrically. As caspase detection is 
not discriminatory of the cell type undergoing apoptosis, it is more useful alongside 
other cell death end point assays. 
 
During the early events of apoptosis, oligo- and mononucleosomes are generated and 
released in the cytoplasm by the internucleosomal cleavage of chromatin (165). These 
cytoplasmic histone associated DNA fragments can be detected via enzyme linked 
immuno assay (ELISA). In this assay cytoplasmic nucleosomes can be immobilised in 
culture plates by sequential administration of antibodies. The first antibody is directed 
against species specific histones, followed by the addition of an antiDNA-antibody 
conjugated to an enzyme. After a final wash step to remove any unbound antibodies, 
an enzymatic substrate is added to produce a visible signal (colormetrically/ 
photometrically). When compared with an internal standard the extent of apoptosis 
activity can be evaluated. 
1.9.1.2 Fluorometric Assays 
Glucose 6-phosphate dehydrogenase (G6PD) is a cytosolic enzyme and is part of the 
pentose phosphate pathway. As G6PD generates NADPH, it plays a crucial role in 
cellular antioxidant defence. G6PD has been shown to leak from cells when its plasma 
membrane integrity is compromised (166). Glucose 6-phosphate (cell death) is 
detected by the coupled-enzyme reaction G6PD to 6-phosphogluconate and the 
reduction of resazurin to a red-fluorescent resorufin (166). The resulting fluorescence 
signal produced by this reaction is proportional to the amount of G6PD released into 
the cell medium. This in turn correlates well with the number of dead cells found in the 
cellular sample.  
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The single cell gel electrophoresis (Comet) assay is used for the evaluation of DNA 
damage and repair. This assay involves the encapsulation of cells in low-melting-point 
agarose followed by cell lysis and electrophoresis of the remaining lysed cellular 
suspension. DNA damage is determined via florescent or silver staining and analysed 
either manually or automatically via imaging software. This process helps in the 
detection of single/ double-strand DNA breaks, DNA cross-links, base/ base-pair 
damages and apoptotic nuclei (167). 
 
An early event within apoptosis is the externalization of phosphatidylserine (PS) to the 
cell surface membrane which serves as a signal by which cells destined for death are 
recognized by phagocytes (168). The annexin V assay uses labelled annexin V protein 
to bind to PS, identifying apoptotic and dead cells which can be counted using flow 
cytometry or fluorescence microscopy. 
 
The detection of nuclear DNA fragmentation and thus apoptosis can also be achieved 
by using the terminal deoxynucleotidyl transferase dUTP Nick End-Labelling (TUNEL) 
assay. Cells undergoing apoptosis cleave their DNA with nucleases leaving free 3’-
hydroxyl ends. The detection of this apoptotic event is achieved via transfer of a 
fluorescent-labelled deoxyuridine triphosphate nucleotide (dUTP) to the free 3’-
hydroxyl ends using the enzyme terminal deoxynucleotidyl transferase (TdT). The 
labelled dUTP can then be detected by light/fluorescence microscopy of flow 
cytometry. Considerations need to be made regarding necrotic cells and those cells in 
the process of DNA repair or gene transcription as they can  produce false positives 
(169). 
 
When the intrinsic apoptotic pathway is triggered, cytochrome c is released from the 
mitochondria into cytosol where it is able to bind to Apaf-1. The resulting cytochrome 
c/Apaf-1 complex activates caspase-9 initiating downstream caspase signalling (170). 
Detection of cell death via the cytochrome c release assay is achieved by detecting 
cytochrome c translocation from mitochondria into the cytosol during cellular 
apoptosis. This can be done on living or fixed cells via fluorescence and electron 
microscopy. 
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1.9.1.3 Chemiluminescent Assays 
The ATP endpoint assays are based on the fact that all living cells require ATP to 
function, whether this be in biosynthesis, cellular signalling or in the cellular structure 
of DNA. The comparison of ATP content from remaining drug exposed cells to those of 
drug free control gives a direct measurement of cellular death and drug potency. This 
assay uses bioluminescence to detect cellular ATP through the conversion of D-
luciferin in the presence of ATP and O2 by the enzyme luciferase to produce AMP, CO2 
and Light (171). This method is able to measure the ATP presence of single cells, with 
ATP concentration being linear up to 108 cells making it highly sensitive (156). 
 
This assay methodology (ATP tumour chemosensitivity assay (ATP-TCA)) has been used 
to assess tumour chemosensitivity in these studies. This method was chosen for its 
superior sensitivity, where the presence of as few as 5 viable cells per well following 
drug exposure can be detected. Fibroblasts, mesothelial cells and other stromal cells 
can proliferate in adherence-based culture systems adding ‘background noise’ to most 
assay types. This phenomenon is minimised in the ATP-TCA by the use of round-
bottomed polypropylene plates, which inhibit cell adherence. The use of a serum-free 
medium also suppresses non-transformed cell proliferation. Unlike other assays the 
ATP-TCA does not require the incorporation of tetrazolium dyes which can have the 
potential for interference with certain drugs (172, 173). A disadvantage to this 
technique is the inability to distinguish between the effects of inhibited glucose 
metabolism/ mitochondrial function resulting in decreased intracellular ATP 
concentrations and drug induced cell death. However, this disadvantage is offset by 
the fact that the ATP-TCA has also shown good correlation between ex vivo sensitivity 
and clinical response in some solid tumours (79, 171, 174-176). 
 
Glyceraldehyde -3-Phosphate dehydrogenase (GAPDH) is an important enzyme in the 
glycolysis pathway, catalyzing the oxidative phosphorylation of D-glyceraldehyde-3-
phosphate to 1,3-diphosphoglycerate. The release of GAPDH from dying cells is 
coupled to the enzyme 3-Phosphoglyceric Phosphokinase (PGK) to produce ATP. The 
ATP can then be detected via luciferin-luciferase bioluminescence methodology 
measuring cytotoxicity and proliferation (177). The generation of ATP is an ongoing 
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process; therefore time point and kinetics methods may also be measured via this 
methodology. 
1.9.1.4 Radioactivity Assays 
The thymidine incorporation assay introduces a radioactive nucleoside (3H-thymidine) 
to proliferating cells. This becomes incorporated into new strands of chromosomal 
DNA during mitotic cell division. The radioactivity of the DNA recovered from the cells 
is used in order to determine the extent of cell division that has occurred in response 
to the drug being tested. 
 
This assay can be adapted to exclude the use of radioactivity by using 5-bromo-2'-
deoxyuridine (BrdU). This BrdU assay detects the incorporation of this pyrimidine 
analog into cellular DNA during proliferation. By using a monoclonal antibody against 
BrdU with an enzyme or fluorochrome conjugated secondary antibody, proliferating 
cells can be detected.  
 
This methodology has been developed further in the form of the Click-iT® EdU assay 
(Life Technologies, UK). Unlike the BrdU assay it does not use antibody based detection 
methods and therefore does not require DNA denaturation. This assay instead uses a 
copper catalyzed covalent reaction between an alkyne and an azide to determine EdU 
incorporated cell proliferation (178). 
1.9.1.5 Real Time Cytotoxic Assays 
Cytotoxic cell based assays usually have finite endpoints where the living/ dead cell 
population is determined.  These assays capture only a snapshot of the incidence of 
cell death and usually require the destruction of the cell to measure outcome. Novel 
assays are now being used to probe and quantify cytotoxicity in real time. These 
include assays that measure plasma membrane integrity markers such as propidium 
iodide (PI), SYTOX Green, SYTOX Red, and YO-PRO 1 (Invitrogen, UK) which can be 
observed via time lapsed microscopy or flow cytometry. Real time cytotoxicity assays 
have also been developed in microfluidic devices, which have the ability to 
characterise drug metabolites and cytotoxicity simultaneously (179). 
31 
 
1.9.2 Serum Tumour Markers 
Serum tumour markers consist of substances that are secreted by tumours and are 
detectable at a level proportional to tumour burden. The use of serum markers to 
measure response to therapy is appealing due to its non-invasive nature and the ability 
to be repeated at every stage of treatment using immunoassays. A few examples of 
serum tumour markers are outlined below. 
 
Carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) are glycoproteins found 
during foetal development. The abnormal presence of these proteins found in some 
cancers and their reduction following tumour resection or chemotherapy has lead to 
their use as markers for tumour response (180-184). 
 
Cancer antigen 125 (CA125) has found a use in ovarian cancer for the detection of 
recurrence following treatment where it is able to identify a percentage of patients 
with asymptomatic recurrence. Evidence suggests that early chemotherapeutic 
treatment of recurrence based solely on CA125 increase does not prolong survival. 
There is still controversy as to the use of CA125 monitoring during follow-up (185-187).  
  
The prostate-specific antigen (PSA) is used in the detection of prostate cancer. In men 
with healthy prostates serum PSA is present in small quantities. However, this level 
becomes increased in prostate related disease including prostate cancer. It has 
become a useful tumour marker for the early detection of prostate cancer (188).  
 
Thyroglobulin (Tg) is a glycoprotein produced solely by thyroid follicular cells. The level 
of Tg is known to be increased in the majority of patients with either benign or 
malignant thyroid nodules (189). This serum tumour marker tested serially over time is 
used to detect residual disease post surgical and radiation treatment (190). 
 
Tissue polypeptide-specific antigen (TPS) is a cytokeratin 18 associated tumour 
proliferation marker, with increased serum levels found at the time of rapid cell 
division (191).  It has been shown to predict response to 5-FU-based chemotherapy in 
patients with advanced colorectal cancer (192).  
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Various tumour markers are available to clinicians to aid diagnosis or determine a 
patient’s response to surgery or chemotherapy; however, many are not tumour 
specific and their use still remains controversial (193). 
1.9.3 Molecular Markers 
There are an increasing number of methodologies used for the detection of molecular 
markers in the study of cancer. The use of molecular markers in predictive and 
prognostic oncology is on the rise, resulting in their use for identification of patients 
most likely to respond to specific therapies as well as those most likely to experience 
disease recurrence, or suffer toxicity.  
 
Tests to detect these markers include assays for molecular or genetic analyses of 
tumour tissue. Detection of mutations in EGFR confers sensitivity to EGFR inhibitors in 
non small cell lung cancer (NSCLC) while mutations in KRAS confer resistance to anti-
EGFR therapy in colorectal cancer (131, 132). The detection of CK19 or mammaglobin 
during intraoperative breast sentinel lymph node testing, infers the presence of 
metastases which requires further surgical treatment (194).  
 
Methodologies used for the detection of such molecular markers are detailed below.  
1.9.3.1 Polymerase Chain Reaction (PCR) 
This technique is based on the ability to take a single copy of a piece of DNA and 
amplify it across several orders of magnitude producing millions of identical copies. 
The DNA sample is subjected to repetitive thermal cycling in which the DNA is first 
heated to allow separation into single strands (denature). The temperature is then 
lowered to allow primers to anneal to their complementary sequences. The 
temperature is then raised to allow DNA polymerase enzymes to attach to the priming 
site and extend new stands of DNA. These denature (94-96 °C), anneal (50-56 °C) and 
extension (72 °C) steps are repeated between 20-40 times resulting in a doubling of 
DNA product at each cycle. 
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The use of quantitative PCR methods allows estimation of the quantity of target DNA 
with a sample. This can be assessed after PCR amplification via gel electrophoresis or in 
real time using fluorescent probes.  
 
As DNA polymerases require a DNA template for PCR, this technique would seem to be 
limited to the analysis of DNA samples. However, the process by which either RNA or 
mRNA can be reverse transcribed into complementary DNA (cDNA) (reverse 
transcription PCR (RT-PCR)) allows for the quantification of gene expression which can 
act as markers for possible response to chemotherapy (195). This response can be 
examined by measuring the abundance of the gene-specific transcript in pre and post 
drug exposure samples. 
 
Real-time PCR (qRT-PCR) using TaqMan probes measures the accumulation of 
fluorescence with each PCR cycle. Fluorescence is measured from the probe containing 
a fluorescent reporter and a quencher. When the probe is intact the fluorescing 
reporter is in close proximity to the quencher allowing the transfer of light emitting 
energy from reporter to quencher. This results in the reporter’s suppressed signal. 
When the PCR enzyme extension phase reaches the annealed probe, the enzyme 
cleaves the probe. A fluorescent emission from the reporter increases as it moves 
further from the quencher.  
 
Interpretation of qRT-PCR can be done in two way quantitatively and qualitatively. 
Qualitative measurement of PCR is used for detecting a specific DNA product. Its 
presence or absence can signify a marker for specific response to treatment (143, 196, 
197).  
 
Quantitative measurement not only detects the presence of a specified DNA product, 
but also deduces its quantity. Absolute quantification requires either a standard DNA 
sample of known quantity for standard curve comparison or for the quantity of DNA 
originally present in a PCR sample to be known. Relative quantification is based on 
stable internal reference genes (housekeeping genes) allowing determination of 
differences of target gene expression (198). 
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Scorpion primers contain a hairpin loop tail consisting of a specific probe sequence, a 
fluorophore and a quencher. The signal from fluorophore attached to the 5’ end of the 
probe is suppressed by the quencher attached to the 3’ end. The hairpin loop is 
attached to the 5’ end of a primer via a PCR blocker. Following the PCR extension 
phase the probe binds to its complementary strand, with this the hairpin loop opens so 
that the fluorophore is no longer quenched and a fluorescent signal is produced (199). 
 
Scorpions can be adapted for use in mutation or allelic discrimination with an 
Amplification Refractory Mutation System (ARMS). The ARMS Scorpions are used to 
both amplify and discriminate between two alleles of a target oligonucleotide. These 
reactions consist of scorpions for each allele. The probe part of the scorpions are 
identical and it is the difference between the primer parts which are used to 
discriminate between the two alleles. This system is already used for the 
characterisation of mutations in EGFR and KRAS to determine the practical use of anti-
EGFR based therapies (200, 201).  
1.9.3.2 DNA Sequencing 
DNA sequencing is used to map out the sequence of the nucleotides (A, T, G and C) 
that comprise a strand of DNA. Through sequencing identification of important genes 
can provide clues about the underlying mechanism of tumour cell biology. Mutations 
identified within these genes have lead to their development as molecular markers for 
the use in identification of effective and non-effective therapies (EGFR in non small cell 
lung cancers (NSCLC) and KRAS in colorectal cancers). Some of the methodologies by 
which these markers are identified are detailed below. 
 
The chain-terminator (dideoxy sequencing/ Sanger) method of sequencing involves 
using a purified DNA polymerase enzyme and a primer specifically constructed so that 
its 3' end is located next to the DNA sequence of interest to synthesize DNA chains of 
varying lengths. This is accomplished through the use of dideoxynucleotide 
triphosphates (ddNTPs) in the reaction mixture in addition to the normal nucleotides 
(NTP’s) found in DNA. These modified dideoxynucleotides lack the 3' hydroxyl (OH) 
group required for the addition of further nucleotides. Following their integration into 
a DNA sequence they effectively terminate the chain. Termination via ddNTP occurs 
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periodically during DNA synthesis resulting in numerous DNA fragments of varying 
length. These can then be separated using gel or capillary tube electrophoresis (202, 
203).  
 
Pyrosequencing is based on the principle of sequencing by synthesis, which detects the 
release of pyrophosphate upon nucleotide incorporation and its reaction with another 
chemiluminescent enzyme. With hybridisation of the primer to the single-stranded 
PCR amplicon serving as a template, sequential addition of deoxribonucleotide 
triphosphates (dNTPs) can begin. Addition of dNTPs is performed sequentially and the 
light produced by each incorporation event is recorded (202).  
 
Like pyrosequencing, the Ion Torrent sequencing method is based on sequencing by 
synthesis. This technology uses an ion sensor to detect hydrogen ions released during 
DNA polymerization. These sensors measure the change in voltage from the release of 
hydrogen ions when the matching nucleotide is added. These readings can then be 
translated into a DNA sequence. 
 
Future technologies are fast approaching with the possible applications of real-time 
sequencing technologies, using single molecule real time sequencing or exonuclease 
nanopore sequencing methodologies (204, 205). 
1.9.4 Microarrays 
Array based technology offers the user the ability to evaluate large numbers of 
experiments simultaneously. Microarray technologies have been widely used to 
research cancer related genetic markers and changes in gene expression (206). 
 
Some of the first array based technology such as the spotted microarrays rely on the 
transfer of probes onto solid surfaces or chips. The cDNA or oligonucleotide probes are 
flooded with a fluorescently labelled sample allowing for the comparison between the 
gene expression of pre and post chemotherapy samples and normal and neoplastic 
cells (207).   
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Real-time PCR arrays have shown some promise for the prediction of tumours to 
chemotherapy (208-210). The use of microfluidic cards to test for tumour gene 
expression profiles lends itself to practical clinical application. Its application reduces 
both lab based work time and the risk of human error associated with manual 
pipetting. 
 
There is an extraordinary potential of microarray technology in the field of clinical 
oncology. Understanding the complexity of cancer has greatly increased the 
understanding of how heterogenic individual tumours can be. Soon diagnosis and 
prediction of response will rely on detection and quantification of multiple markers 
provided by array based technology.   
1.9.4.1 Microsatellite Instability Testing 
Microsatellites are short repeating sequences of DNA usually 2-6 base pairs in length. 
These repeated sequences are both common and normal; however cells that have 
mutations in DNA repair genes can accumulate errors in these regions resulting in 
these repeated sequences becoming longer or shorter. The manifestation of unusually 
long or short microsatellites within a person’s DNA is referred to as microsatellite 
instability (211). 
 
Microsatellite instability (MSI) can be associated with defective DNA mismatch repair 
in various solid tumours including endometrial, ovarian, colorectal and gastric cancers 
(211-213). Although microsatellite instability status has shown to be a good prognostic 
factor for colorectal tumours, its predictive value for chemosensitivity remains 
controversial (214-217). 
 
Analysis of MSI involves the comparison of the allelic profiles of both microsatellite 
markers generated by amplification of DNA and from matching normal and test 
samples. Positive MSI results in the presence of alleles in the test sample which are not 
found in the corresponding normal samples. 
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Chapter 2 -  Materials and Methods 
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2.1 Introduction 
This chapter describes the various methods used during the experimental aspect of 
this PhD.  
2.2 ATP-TCA 
The ATP-Based tumour chemosensitivity assay (ATP-TCA) was performed as described 
Andreotti et al., (1995). This assay is available in kit form from DCS Innovative 
Diagnostik Systeme (Hamburg, Germany) as the TCA-100 kit though an in house 
method was used here. This method is described below. Methods were carried out in 
accordance with the control of substances hazardous to health (COSHH) regulations 
and under standard laboratory safety regulations to Good Laboratory Practice 
standards using standard operating procedures. 
2.2.1 Preparation of Assay Reagents 
Preparation of assay reagents was performed under sterile conditions within a BioQ 
Microfuge Class II Hood. All ATP-TCA assays for both human specimens and cultured 
cells were carried out in Complete Assay Medium (CAM) (available from DCS 
Innovative Diagnostik Systeme, Hamburg, Germany). This medium is serum free and 
does not contain growth factors. To prevent infection CAM is supplemented with 100 
IU/ml penicillin and 100 μg/ml streptomycin (Sigma Chemical Co Ltd, Poole, Dorset, 
Cat No. P0781) and also 10 mM HEPES (Sigma H9136).  
2.2.2 Transportation of Tumour Material 
Ethics was approved for the use of excess tumour tissue not required for diagnosis 
((07/MRE08/2) North West Research Ethics Committee).  
 
Solid tumour material was transported in universals containing 10 ml Dulbecco’s 
Modified Eagles Medium (DMEM) (Sigma D6171) to which 100 IU/ml penicillin and 100 
µg/ml streptomycin (Sigma P0781), 10 mg/ml gentamicin (Sigma, UK; G1272) and 10 
mM HEPES (Sigma H0887) has been added. Tissue from potentially contaminated 
sources (such as those who come in contact with the body’s natural flora) were 
transported in the same medium, with 2.5 µg/ml amphotericin B (Fungizone, A2942; 
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Sigma) and 1 µg/ml metronidazole (Flagyl®; Rhône Poulenc Roreer Limited, 
Eastbourne, UK). 
 
Ascites samples, as well as pleural fluids, were transported in 250 ml bottles, 
containing 25 ml DMEM (Sigma D5671) to which 100 IU/ml penicillin, 100 µg/ml 
streptomycin (Sigma P0781) and 10 mM HEPES (Sigma H9136) has been added. As a 
precaution to prevent blood clots forming while in transit 5000 IU heparin sodium 
(Monoparin®, CP Pharmaceuticals Ltd, Wales) was added. 
 
Tumour samples that required overnight delivery were packed in a polystyrene box 
and kept chilled with an icepack. To prevent freezing, which would result in cell death 
and an inadequate cell yield for assay; the sample was separated from the icepack by 
paper towels. The sample along with its paper work, including patient history details 
and consent form was then sent via overnight delivery. 
 
2.2.3 Initial Preparation of Tumour Samples 
Upon receipt of solid tumour specimens, samples were placed into a 100 mm diameter 
x 15 mm deep sterile petri-dish. Excess fat and connective tissue was excised and 
discarded. The sample was then dissected into 0.5 – 2.0 mm3 pieces using sterile 
scalpels and transferred into universals containing a previously prepared enzyme 
solution. If the tumour sample was large, i.e. greater than 5 x 10 x 10 mm, then more 
than one container was set up with equal amounts of tumour material going into each 
digest. The dissected sample was gently digested overnight in the collagenase solution 
(Sigma, UK; C8051) reconstituted with Complete Assay Medium (CAM; DCS Innovative 
Diagnostik Systeme, Germany) and incubated at 37°C and 5% CO2 (Table 1). The 
mixture was shaken or inverted at intervals to disrupt the specimen and encourage 
dissociation. 
Table 1: Collagenase concentrations used to digest different tumour tissues 
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Following overnight digestion the sample was removed from the incubator, gently 
inverted forming a homogenous cell suspension, then replaced back into the incubator 
for 30 minutes. 
 
Ascites samples already being single cell suspensions, do not require enzymatic 
dissociation. These samples were split equally and aliquoted into 50 ml universals 
under sterile conditions. The samples were centrifuged at 300 g for 10 minutes and the 
supernatant discarded.  
 
The dissociated cells were washed in a medium consisting of DMEM supplemented 
with 1 M HEPES, 100 IU/ml penicillin, 10 mg/ml streptomycin and 10 mg/ml 
gentamicin. Media was added to the samples which were then centrifuged at 300g for 
10 minutes. The supernatant was discarded and the process repeated. The 
supernatant was kept separate from the sample after each wash until the cells had 
been counted. After the second wash the cells were resuspended in 10 ml CAM (less if 
the specimen was small) and the universal was stood vertically to allow any undigested 
material to sediment out. 
 
The cell viability and concentration were then assessed using the trypan blue exclusion 
method. If tumour cells were present, viable cells were separated from erythrocytes 
and debris using Ficoll-Hypaque density gradient separation. 
2.2.4 Trypan Blue Exclusion  
Cell number and viability were routinely assessed using a haemocytometer and the 
trypan blue exclusion method. Equal volumes of cell suspension and a 0.4% solution of 
trypan blue (Sigma T8154), normally 20 µl, were mixed in a polypropylene (Eppendorf) 
container and pipetted onto the haemocytometer. Dead or dying cells are unable to 
pump trypan blue out of the cytoplasm and so appear blue under the microscope, 
while viable cells remain clear (218).  
 
As well as assessing the percentage of viable cells within a sample, this method also 
allowed the amount of non-tumour cells to be estimated. It was not uncommon to find 
non-tumour cells in samples; these included mainly red blood cells. These were 
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removed by Ficoll-Hypaque density gradient separation (see next section). The use of 
specialised media (CAM) and polypropylene culture plates ensured that lymphocytes 
and other non-malignant cells did not survive in culture and therefore did not interfere 
with the assay result (171). 
2.2.5 Ficoll-Hypaque Density Gradient Separation 
Ficoll-Hypaque density gradient separation (219) was performed following the 
manufacturer’s instructions. 10 ml of Ficoll-Hypaque (Histopaque; Sigma 1077-1) was 
pipetted into sterile polystyrene 30 ml universal containers. Equal volumes of the 
digested specimen was carefully layered on top of the Ficoll-Hypaque using a sterile 
Pasteur pipette and tilting the universal at a 45° angle taking care not to mix the two 
layers. The sample was then centrifuged at 400 g for 30 minutes at room temperature. 
After this period the blood cells were sedimented as a pellet, leaving the tumour-
derived cells forming an interface between the Ficoll-Hypaque and CAM. The interface 
containing the purified tumour cell suspension was transferred into a separate sterile 
30 ml universal using a sterile Pasteur pipette. The cells were then washed twice with 
10 ml CAM by centrifugation at 300g for 10 minutes. Cell number and viability were 
then reassessed using the trypan blue exclusion method. 
2.2.6 Preparation of Chemotherapeutic Agents 
Standard cytotoxic drugs used in the assay were obtained as vials for injection from 
the pharmacy at Queen Alexandra Hospital in Portsmouth where available. All of the 
chemotherapeutic drugs or combinations were tested in triplicate at 6 dilutions, 
corresponding to 200%, 100%, 50%, 25%, 12.5% and 6.25% of the estimated Test Drug 
Concentration (TDC). The TDC is based on the peak plasma concentration and the 
protein binding for the individual drugs and has been adjusted to provide correlation 
with clinical response rates (171). In each 96-microwell culture plate four drugs or drug 
combinations can be tested. The remaining wells in the plate were used for maximum 
inhibitor (MI) and no drug media only (MO) controls. The plate design used is shown in 
Figure 5. All the chemotherapeutic drugs were prepared following manufacturer’s 
instructions and divided into aliquots which were then stored either at room 
temperature, 4°C, -20°C or -80°C (220). A list of all the drugs used including the stock 
and test drug concentrations can be found in Table 2. 
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Figure 5: Plate layout 
An 800% test drug concentration (TDC) solution of each drug to be tested was 
prepared by diluting the stock solution into 2 ml, 5 ml or 10 ml of complete assay 
media (CAM). Table 2 shows the volume that needs to be added to 5 ml CAM to obtain 
an 800% TDC solution, as well as the TDC for all the drugs used in this study. Drug 
combinations were tested by adding the constituent drugs together at their 800% TDC 
at the beginning of the assay before serially diluting them. 
Table 2: Drug stock and test drug concentrations  
 
Drug
Test Drug 
Concentration 
μg/ml
Stock 
Concentration 
mg/ml
Test Drug 
Concentration  μM
Molecular 
weight
Cetuximab 185 2 1.27 145781.6
Cisplatin 3 1 10 300.1
Erlotinib 1.4 5 3.26 429.9
Farnesol 2 5 10 222.37
Farnesyl Diphosphate 4 12 23 382.326
Fluvastatin 5.0 12.5 12 411.5
Gefitinib 0.4 1 1 446.9
Gemcitabine 12.0 40 40 299.7
Geranylgeraniol 5 20 10 450.449
Mevalonate Low 0.7 4 5 148.16
Mevalonate Medium 30 4 200 148.16
Mevalonate High 228 4 1537 148.16
Paclitaxel 13.6 6 16 853.9
PD98059 13.4 5 50 267.28
Sirolimus 0.9 0.46 1 914.2
Treosulfan 20 50 72 278.3
Zoledronic acid 10 0.8 34 290.1
ZSTK474 0.45 2 1.08 417.4
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2.2.7 Drug Panel for ATP- Assay’s 
The panel of drugs used for each assay was chosen after researching relevant literature 
and consultation with Professor Cree. The concentrations of these agents were 
determined from phase 1 data, corresponding literature and discussions with 
Professor Cree. 
2.2.8 Preparation of 96 Well Plates 
ATP-TCAs were performed in round bottomed polypropylene plates (Corning Life 
Sciences, UK; 3790). 100 µl of CAM was pipetted into each well of rows B-H with a 
multi-channel pipette. The pre-prepared 800% TDC drug dilution (100 µl) was added to 
triplicate wells of row B. Using a multichannel pipette the drugs were serially diluted 
down the plate from rows B-G, while the excess 100 µl remaining after the serial 
diluting was discarded giving dilutions corresponding to 200-6.25% of the TDC. Two 
controls were included in each plate: a no drug control consisting of media only (MO) 
in row H corresponding to 100% viable cells and a maximum inhibitor (MI) control in 
row A which killed all cells present giving a zero ATP count. The MI solution was made 
up of 0.02% v/v Triton X-100 (Sigma, UK; T8787) in DMEM. The plate was now ready 
for addition of the tumour cells. 
 
Cells obtained from enzymatic dissociation of solid tumour material or malignant 
effusions as described previously were adjusted to 200,000 or 100,000 cells/ml in CAM 
respectively. 100 µl of cell suspension was then added to each well of the 96-microwell 
plate giving final cell concentrations of 20,000 for solid tumour specimens and 10,000 
for the ascites specimens. Plates were incubated in a 95% humidified, 37°C, 5% CO2 
incubator for 6 days, and checked periodically for overgrowth and infection. After the 
incubation period the ATP was extracted from the cells and measured. 
 
Any cells that were not required for assays were cryopreserved in DMEM 
supplemented with 100 IU/ml penicillin and 100 µg/ml streptomycin, 10% foetal calf 
serum (FCS) (Labtech International, East Sussex, UK, cat. 4-101-500) and 10% DMSO 
(Sigma D5879) or the complete cryopreservation medium- recovery culture cell 
freezing media (Life Technologies, Paisley, UK, cat. 12648-010).  
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2.3 ATP Extraction and Measurement 
2.3.1 ATP Extraction 
A reagent for the extraction of ATP was prepared. HEPES buffer powder (101.7 mg/ml; 
Sigma H-4034), ammonium meta-vanadate (1.267 mg/ml; Sigma A-1183) and Triton X- 
100 (0.5%; Sigma T-8787) were dissolved in sterile water (B.P. Water for Irrigation, 
Pharmacy, Queen Alexandra Hospital), and the solution was titrated to pH=7.8 with 5.0 
M sodium hydroxide. The solution was then left to stand overnight in a sterile safety 
cabinet uncovered until the colour of the liquid changed from yellow to clear. The 
solution was then filter-sterilised using a 0.22 µm filter and 20 ml syringe and aliquoted 
into 30 ml sterile universal containers, which were stored in the refrigerator. ATP was 
extracted from cells by the addition of 50 µl of ATP extraction reagent to each well of 
the 96-well plate. The cells were immediately mixed by gentle pipetting 4-6 times using 
a multichannel pipette. Pipette tips were discarded after each drug triplicate. Plates 
were incubated at room temperature for a minimum of 20 minutes and a maximum of 
one hour before the ATP was read. 
2.3.2 Preparation of Reagents 
The ATP in the wells was measured using a luciferin-luciferase counting reagent. D-
luciferin (Cat. 800-LN) and recombinant luciferase (Cat. 700-LF) were purchased from 
R&D systems (Abingdon, UK) and a luciferin-luciferase counting reagent was prepared 
as described below.  
 
Firstly, a 10x HEPES buffer was prepared by mixing 4.766 mg/ml HEPES powder (Sigma 
H-0887) and 1.22 mg/ml magnesium sulphate heptahydrate (Sigma M-9397). The 
solution was basified to pH=7.7 with sodium hydroxide and filter sterilised; D-luciferin 
was then dissolved in it (0.732 mg/ml buffer). Secondly, a 0.5 M Tris-succinate buffer 
containing 1% BSA was prepared by dissolving 0.226 mg/ml TRIZMA®-succinate (Sigma 
T-9632) and 25.9 µl /ml bovine albumin 35% solution (Sigma A-7409), and adjusted to 
pH=7.5 with sodium hydroxide. This buffer was used to reconstitute the recombinant 
luciferase (1.0 mg/ml); the solution was then incubated on ice for 1 hour to let the 
luciferase dissolve completely. The final reagent was then prepared combining 102.5 
ml of 10x HEPES buffer containing D-Luciferin with 24.75 ml of recombinant luciferase 
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(1.0 mg/ml) in 0.5 M Tris-succinate buffer and 41.25 ml of 3% BSA. All incubations 
were performed in light-tight vials. 
 
The solution was stored at -20°C in 2.0 ml aliquots in light-tight boxes. Before use each 
2.0 ml aliquot was diluted with 18 ml of dilution buffer, which consisted of a 1 in 10 
dilution of the HEPES buffer prepared to dissolve D-luciferin. ATP was measured using 
a Berthold Diagnostic Systems MPL1 luminometer (Berthold Diagnostic Systems, 
Pforzheim, Germany). All luminescence measurements were performed using the 
manufacturer’s instructions. 
 
The Adenosine 5’-triphosphate standard disodium salt hydrate (Sigma, UK, cat. FLAAS-
1VL) was reconstituted using sterile water to give a final concentration of 250 ng/ml. 
The solution was filter sterilised through a 0.2 µm filter and aliquoted into 40 µl 
aliquots, stored at –20°C and protected from light for a maximum time of 6 months. 
2.3.3 ATP- Standard Curve 
An ATP standard curve was performed as a quality control prior to reading any ATPTCA 
plates, to ensure that all reagents and equipment were functioning properly. For this 
procedure, 50 µl of dilution buffer was added to nine wells of a white 96 well 
microplate (Thermo Life Sciences, UK, cat. 7905). To prepare the ATP, 10 µl of the 
previously aliquoted 100 µg/ml stock solution was added to 4 ml of dilution buffer 
giving a 250 ng/ml ATP solution; 25 µl of this was added to the first well of the white 
plate containing dilution buffer. The solution was mixed using the pipette and then 25 
µl was transferred to the 2nd well. The mixing was repeated through to the ninth well 
to give final ATP concentrations of 83.33; 27.76; 9.253; 3.084; 1.028; 0.342; 0.114; 
0.038 and 0.012 ng/ml. 50 µl of luciferin-luciferase reagent, was added to each of the 
nine wells and the plate placed into a luminometer (MPL1, Berthold Diagnostic 
Systems, Germany). The light output, which is directly proportional to ATP 
concentration, was then measured. For the test ATP-TCA to be evaluable the average 
MO reading must reach that of the 1.028 ng/ml ATP value in the standard curve (Figure 
6- ATP Standard curve). 
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Figure 6: ATP standard curve produced on a Berthold plate luminometer 
2.3.4 Reading of ATP-TCA Plates 
At the end of the incubation period (either 5/6 days), cells in the TCA plates were 
checked for the presence of infections (if any problems were observed the plate was 
discarded). On rare occasions, single wells were found to be infected and these were 
excluded from analysis. To read the ATP levels in the ATP-TCA plates following cell lysis 
(ATP extraction), 50 µl from each well of the 96-well culture plate was transferred into 
a fresh white 96-well plate (Corning, UK, cat. 3362), using fresh pipette tips for each 
drug triplicate. To each well, 50 µl of the previously prepared luciferin-luciferase 
counting reagent was added and the luminescence was read using the luminometer, 
following the manufacturer’s operating instructions. 
2.4 Data Capture and Analysis 
2.4.1 Data Capture and Calculation of Sensitivity 
The data produced from each ATP-TCA plate was entered into an Excel (Microsoft®) 
spreadsheet that calculated the percentage tumour growth inhibition at each 
concentration, the IC50, IC90 (concentration of drug required to cause 50% and 90% 
inhibition) and the area under the concentration vs. inhibition graph (IndexAUC) for 
each drug. The percentage tumour growth inhibition at each drug concentration was 
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used to plot curves for each drug or combination. As the variation between the wells 
that were averaged to calculate the percentage tumour inhibition is small (typical 
coefficient of variance of less than 10%), error bars have not been included on most 
graphs as they are usually smaller than the markers on the graphs. The percentage 
tumour growth inhibition was calculated as follows: 
 
 
 
 
Test = mean counts for test drug wells 
MI = mean counts for maximum inhibitor wells 
MO = mean counts for medium only wells 
 
To make comparison between different tumours easier a sensitivity index (IndexSUM) 
for each drug in each tumour was calculated. This involved summing the percentage 
tumour growth inhibition and subtracting this figure from 600 (IndexSUM = 600 -Sum 
[Inhibition 6.25.........200]). It has been suggested that IndexSUM values >350 confer 
comparable clinical resistance, values <300 confer comparable clinical sensitivity and 
values between 300 and 350 confer equivocal sensitivity (221, 222). 
2.4.2 Calculation of Synergy 
The effects of drug combinations compared with their single agent counterparts were 
analysed using the methods determined by Poch et al (223, 224) which compares the 
expected (additive) effect with the actual achieved effect at each drug concentration. 
This method is often better suited to the data produced by the ATP-TCA than other 
methods commonly used to evaluate combination as it is able to deal with drugs which 
produce a shallow dose response curve. 
 
Combination indices (CI) calculated by the Chou and Talalay (225) methods were 
determined at 50% and 90% cell death. These were defined as follows: 
 
CIA+B = [(DA/A+B)/DA] + [(DB/A+B)/DB] + [α(DA/A+B x DB/A+B)/DADB] 
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Where CIA+B = CI for a fixed effect (F=50% or 90%) for the combination of cytotoxic A 
and cytotoxic B; DA/A+B = concentration of cytotoxic A in the combination A + B giving 
an effect F; DB/A+B = concentration of cytotoxic B in the combination A + B giving an 
effect F; DA = concentration of cytotoxic A alone giving an effect F; DB = concentration 
of cytotoxic B alone giving an effect F. α= parameter with value 0 when A and B are 
mutually exclusive and 1 when A and B are mutually non-exclusive. The combination 
index CI calculates synergism <0.8; additivity >0.8 and <1.2; antagonism >1.2 (226). 
2.5  ATP – Sequential Assay (ATP-TSCA) 
The ATP – sequential assay (ATP-TSCA) was developed in order to obtain sequential 
information regarding drug sensitivity or resistance in samples when one drug is given 
before another. This method is comparable to the standard ATP-TCA, but modified to 
determine the effects of sequential treatment. The method and development of this 
assay are described in Chapter 3.3: Methods and Results ATP – Sequential Assay (ATP-
TSCA). 
2.6 Sequential Molecular Biology Plate  
This plate was produced alongside the standard ATP-TCA and ATP-TSCA plates for 
inclusion in the sequential TaqMan array studies. Plates were split into two halves, one 
half containing the media only control cells and the other the relevant drug (Drug used 
for pre-treatment in sequence assay). The plates were incubated for 24 hours before 
cells were harvested and stored in RA1 2ME where at a later date RNA could be 
extracted and multiple targets tested in a TaqMan Low Density Array (TLDA). 
2.7 RNA Extraction 
2.7.1 Nucleic Acid Isolation and Digestion 
This process was completed using the Ambion® RecoverALL™ Nucleic acid Isolation kit 
using their total nucleic acid isolation protocol (Life Technologies, Paisley, UK, cat. 
AM1975). 
 
Sample lysates were slowly thawed from -20˚C to 7˚C in the fridge, and then allowed to 
come to room temperature. During this time, vials of nuclease free water were pre-
heated to 95˚C in a heat block. Once thawed 100% ethanol was added to each sample 
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and carefully mixed via pipetting. Samples were then added onto the pre-prepared 
filter spin columns and the lids closed. Samples were then centrifuged at 10,000g for 
30-60 seconds passing the lysate through the filter. The flow through was then 
discarded and the filter cartridge re-inserted into the same collection tube. This 
process was repeated until all the lysate sample mixture had passed through the filter. 
Following filtration, the samples underwent two wash steps. Wash 1 consisted of 
adding 700 μl of wash 1 to the filter followed by centrifugation at 10,000g for 30 
seconds. After discarding the flow through 500 μl of wash 2/3 was added to the filter 
and again passed through the filter. After the second wash step the flow through was 
discarded and the filter cartridge replaced back into the same collection tube, the 
assembly was then spun again to remove any residual fluid from the filter. 
 
The following solutions were combined to make a DNase mix (Table 3). When multiple 
samples were being processed a master mix was made. Each sample had a 60 μl DNase 
mix added to the centre of the filter cartridge. The tubes were capped and then 
incubated at room temperature for 30 minutes. After incubation with the DNase mix 
the samples were washed as before once with 700 μl of wash 1 and then twice with 
500 μl of wash 2/3. They were then spun a further time to remove residual fluid. The 
fluid free filter cartridges were then transferred to fresh collection tubes where the 
nucleic acid could be eluted. Nuclease free water (55 μl) pre-heated to 95˚C was 
applied to the centre of the filter and allowed to sit at room temperature for 1 minute 
with the cap closed. The nucleic acid was then eluted from the filter via centrifugation 
at maximum speed and collected in the collection tube. A second 55 μl of nuclease 
water was used to elute further nucleic acid into the same collection tube leaving a 
total close to 110 μl of collected eluate. Samples were then quantified and purity 
checked using 1.3 μl of each undiluted sample with the NanoDrop spectrophotometer.  
Table 3: DNase and master mix concentrations. 
 
 
 
 
50 
 
2.7.2 Reverse Transcription 
Isolated RNA was immediately converted into cDNA using ABI High Capacity cDNA 
conversion kits. Samples were diluted when necessary in nuclease free water (final 
volume 105 µl) to give a working concentration of approximately 100 ng/µl. Data from 
NanoDrop readings were inputted into an Excel workbook (Microsoft®) which 
performed the dilution calculations necessary to complete cDNA and RT Negative 
reaction mixes. These mixes were added and chilled in a cooling block until ready to 
load into the Thermal Cycler (Peqlab, UK). Thermal cycler conditions were set to the 
manufactures ‘manual method’ settings. After the run was completed samples were 
pulse microfuged at 10,000g for 30 seconds before cDNA quantity was checked via a 
NanoDrop spectrophotometer (Thermo, UK) ready for future PCR based experiments. 
2.8 DNA Extraction 
2.8.1 Nucleic acid Isolation and Digestion 
This process was completed using the Ambion® RecoverALL™ Nucleic acid Isolation kit 
using their total nucleic acid isolation protocol. 
 
Sample lysates were slowly thawed from -20˚C to 7˚C in the fridge; then allowed to 
come to room temperature. During this time vials of nuclease free water were pre-
heated to 95˚C in a heat block. Once thawed 100% ethanol was added to each sample 
and carefully mixed via pipetting. Samples were then added onto the pre-prepared 
filter spin columns and the lids closed. Spin columns were then centrifuged at 10,000 g 
for 30-60 seconds passing the lysate through the filter. The flow through was then 
discarded and the filter cartridge re-inserted into the same collection tube. This 
process was repeated until all the lysate sample mixture had passed through the filter. 
Following filtration the samples underwent two wash steps. Wash 1 consisted of 
adding 700 μl of wash 1 to the filter followed by centrifugation at 10,000 g for 30 
seconds. After discarding the flow through 500 μl of wash 2/3 was added to the filter 
and again passed through the filter. After the second wash step the flow through was 
discarded and the filter cartridge replaced back into the same collection tube; the 
assembly was then spun again to remove any residual fluid from the filter. 
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The following solutions were combined to make an RNase mix (Table 4). When 
multiple samples were being processed a master mix was made. Each sample had a 60 
μl RNase mix added to the centre of the filter cartridge. The tubes were capped and 
then incubated at room temperature for 30 minutes. After incubation with the RNase 
mix the samples were washed as before once with 700 μl of wash 1 and then twice 
with 500 μl of wash 2/3. They were then spun a further time to remove residual fluid. 
The fluid free filter cartridges were then transferred to fresh collection tubes where 
the nucleic acid could be eluted. Nuclease free water (55 μl) pre-heated to 95˚C was 
applied to the centre of the filter and allowed to sit at room temperature for 1 minute 
with the cap closed. The nucleic acid was then eluted from the filter via centrifugation 
at maximum speed and collected in the collection tube. A second 55 μl of nuclease 
water was used to elute further nucleic acid into the same collection tube leaving a 
total close to 110 μl of collected eluate. Samples were then quantified and purity 
checked using 1.3 μl of each undiluted sample with the NanoDrop spectrophotometer. 
Table 4: RNase and master mix concentrations. 
 
 
2.9 Calculation of DNA and RNA with NanoDrop 
The NanoDrop spectrophotometer was used to quantify gDNA, RNA and cDNA 
samples. Prior to sample reading the computer software needs to be opened and the 
correct sample type highlighted. Each measurement session always began with a 
blanking cycle. This assures the instrument is working well and that any buffer 
absorbance is not a concern. Before administration onto the measurement pedestal 
tubes were vortexed to ensure samples were mixed thoroughly. Once administered 
the sampling arm was then closed and the spectral measurement initiated. Between 
sample measurements both the upper and lower pedestals were wiped clean using a 
soft laboratory wipe, thus preventing sample carryover in successive measurements. 
The NanoDrop software uses Beer’s law to calculate sample concentration in ng/µl 
based on absorbance at 260 nm.  The following absorption coefficients were used: (i) 
ds DNA: 1.0 absorbance units at 260 nm in a 1 cm cuvette = 50 µg/ml, (ii) RNA: 1.0 
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absorbance units at 260 nm in a 1 cm cuvette = 40 µg/ml. Purity is also measured and 
is calculated by the ratio of sample absorbance at 260 and 280 nm. Ratios of ~1.8 for 
DNA and ~2.0 for RNA are generally accepted as pure. If the ratio is noticeably lower in 
either case, it may indicate the presence of protein, phenol or other contaminants. 
Sample data is automatically stored in archive files and easily retrieved when needed. 
2.10 Running the TaqMan Low Density Array (TLDA) 
The TLDA is comprised of a 384-well micro fluidic card, designed to be used within an 
Applied Biosystems 7900HT Fast Real-Time PCR System (Figure 7). Hundreds of real-
time PCR reactions can be performed simultaneously with minimal amounts of sample, 
allowing 1 to 8 samples to be run in parallel against 12 to 384 targets. Targets were 
chosen after researching relevant literature and looking for targets that were 
presumed relevant in cell proliferation and differentiation, drug pumps and 
detoxification, DNA damage and repair, apoptosis as well as others more specific to 
cell and drug type (Table 5). The panel also included four housekeeping genes used for 
controls. 
 
TaqMan arrays were run according to manufacturer's instructions. Each sample was 
made up with TaqMan ×2 Universal Master Mix and mixed with an equal volume of 
cDNA to give a final concentration of 300 ng/μl. All four samples were then pipetted 
into two consecutive ports (100 μl per port) of the 384 well cards. The loaded TaqMan 
array was then placed, port side upwards, into a balanced centrifuge (Sorval Legend) 
and spun at 380 g for 1 minute to fill the card. This was checked and the card spun 
again to remove any air bubbles. The card was then placed into a TaqMan array slide 
sealer, sealed, and the loading ports cut from the card before being loaded into an AB 
7900HT thermal cycler. PCR was performed for 90 min with the following conditions: 
AmpErase UNG Activation for 2 min at 50°C; AmpliTaq Gold DNA Polymerase 
Activation for 10 min at 94.5°C; followed by 40 cycles each of Melt Anneal/Extend for 
30 sec at 97°C and 1 min at 59.7°C. The 'Auto Threshold Cycle' function was performed 
at the end of the run and resulting cycle threshold (Ct) data from the array card was 
transferred to a Microsoft Excel spreadsheet. Controls were checked, and the data 
transferred to a Microsoft Access database before further analysis. 
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Ct values were standardised by reference to porphobilinogen deaminase (PBGD), the 
least variable housekeeping gene of the four present on the array. Standard methods 
of PCR analysis (delta Ct) were not used in analysis of this assay.  Instead these studies 
used a logarithmic gene expression ratio (GER) calculated as Ln(2-Ct(test)/2-Ct(PBGD)) and 
used for comparison with ATP-TCA data. 
 
As these studies were performed over a prolonged period of time, during the course of 
experimentation standard control material obtained from pooled cDNA samples were 
run alongside non template controls (NTC) and RT negative samples testing card and 
sample Ct variability.  
 
Figure 7: TLDA microfluidic Card (adapted from TaqMan array microfluidic cards user 
guide) 
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Table 5: Genes included on TaqMan array, classified by their major contribution to 
drug resistance mechanisms. 
 
Apoptosis DNA repair  Proliferation Pumps/Detox
AKT ATM kinase APC C-term ATP7B
APAF1 BRCA1 APC N-term BCRP
BAD ERCC1 β TUBULIN III CES1
BAX ERCC2 COX2 CES2
BCL2 GTF2H2 EGFR cN II
BCL-x(L) MGMT HER2 DPD
BID MLH1 HER3 FPGS
c-FLIP MSH2 HER4 γH2AX
FAS MSH6 HIF1A GCLC
FASL RAD51 KI67 GCLM
HSP60 TOPO I P16 GSTπ
HSP70 TOPO IIα P21 hENT1
HSP90 TOPO IIβ P27 hENT2
IAP2 XPA P53 MDR1
IGF1 XRCC1 TS MRP1
IGF1R XRCC5 VEGF MRP2
IGF2 XRCC6 MRP3
IGF2R MRP4
IGFBP1 MRP5
IGFBP2 MRP6
MCJ MRP8
MCL1 MTII
mTOR MVP
NFκB House-keeping gene OPRT
PIK3CA 18S RRMI
PTEN HPRT SOD1
STAT3 PBGD TAP1
SURVIVIN SDHA TAP2
XIAP TBP TAP4
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2.11 Analysing TaqMan Low Density Array Raw Data 
TaqMan data was analysed using a logarithmic gene expression ratio. The cycle 
number is first converted to presumed copy number (i.e. 2-Ct) based on data having 
similar primer efficiencies. This allows the gene expression ratios to be obtained 
without skewing the data. It is then standardised against the best housekeeping gene 
for that data series (i.e. 2-Ct(test)/2-Ct(PBGD)) Data is then normalised by natural log 
transformation of this value, (i.e. Ln(2-Ct(test)/2-Ct(PBGD))).  
2.12 TaqMan Low Density Array Descriptive and Inferential Statistical 
Analysis 
Descriptive statistics such as mean, median, range, variation and distribution were 
calculated via Microsoft Excel 2007 spreadsheets using relevant statistical function 
formulae. 
 
Correlation was calculated using Pearson’s correlation coefficient (r). This is calculated 
as a measurement of the strength associated between two variables.  
 
 
 
 
 
The closer the scatter of points is to a straight line, the higher the strength of 
association between the variables. Data ranges from -1 to +1 with zero indicating no 
linear relationship. Positive correlated variables increase or decrease together, while 
negative correlated variables increase as the other decreases and vice versa. It should 
also be considered that just because two variables are related, it does not 
automatically mean that one variable directly causes the other. 
 
Significance of correlation was calculated with GraphPad InStat3 (www.graphpad.com) 
using the two-tailed P value where normality and random sampling was assumed. The 
resulting P value answers the question that if the two variables really are not 
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correlated at all, what is the chance that randomly selected subjects would have a 
correlation coefficient as large as that observed in the analysed experiment. 
2.13 Cell Culture 
Chosen from an in-house panel (TORC-20), cell lines were selected for their close in 
vitro resemblance in terms of chemosensitivity in the ATP-TCA to human tumour 
derived cells harvested directly from patients (227). These were purchased from either 
ATCC (LGC Promochem, Middlesex, UK) Cancer Research UK or donated from Horizon 
Discovery (Cambridge, UK). Cell lines were supplied as frozen aliquots and 
subsequently grown under the direct methods from the companies obtained. All cell 
lines grew as adherent cultures. 
2.13.1 Cell Lines 
Cell lines in this study included cells originating from ovarian (JAMA2), breast 
(MCF10a), lung (NCI-H23) and oesophageal (OE19) tissue. Cell lines were expanded for 
3 passages from the frozen aliquots received to produce a stock prior to 
experimentation and did not exceed 10 passages in total. This kept any long term 
culture changes from affecting cellular assay results. 
2.13.2 Cell Culture Media 
All cell lines were grown in standard growth medium specified by the corresponding 
company of purchase. These were supplemented with 10% foetal calf serum (FCS) 
(Labtech International, East Sussex, UK, cat. 4-101-500) or 5% horse serum (Invitrogen, 
Paisley, UK, cat. 26050-088), 100 IU/ml penicillin and 100 μg/ml streptomycin (Sigma 
P0781). The cells were incubated at 37°C in a humidified 5% CO2 incubator until they 
were sufficiently confluent. Prior to experimentation, Ficoll-Hypaque density gradient 
centrifugation was used to separate pure cell populations from debris or dead cells, 
followed by viability estimation and cell counting by Trypan blue exclusion as 
previously described in paragraph 2.2.4. 
2.13.3 Passaging Cell Lines 
When sufficiently confluent, adherent cell lines were trypsinised using a 1:10 dilution 
of a 10x trypsin-EDTA solution (5.0 g/L trypsin in 0.2% EDTA; obtained either from 
GIBCO BRL, Cat. 35400-027, or from Sigma, Cat T4174) flasks were washed with 
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phosphate buffered saline to remove traces of serum containing media before the 
addition of trypsin. Trypsinisation could be sped up by putting the flask containing the 
trypsinised cells into the incubator for no longer than 3 minutes. After cells were 
completely detached from the flask, the trypsin activity was inhibited by the addition 
of growth media containing foetal calf serum (FCS) and the cells pelleted by 
centrifugation at 300g for 10 minutes before being washed twice in growth media to 
remove any traces of trypsin. The cells were counted using the trypan blue exclusion 
method as described in paragraph 2.2.4. Cells were then ready for either 
experimentation or further culturing.  
2.13.4 Seeding Cell Line Flasks and Cell Line Plates 
Cells were seeded according to supplier’s guidelines while taking in to account of 
doubling times. Cells were reconstituted from frozen pellets stored in a liquid nitrogen 
dewar and defrosted under cold running water. Once defrosted, vials were wiped with 
an alcohol soaked towel and placed into the class 2 safety hood. The cells were added 
drop wise to a 30 ml universal containing 10 ml of pre-warmed growth media. Cells 
were centrifuged at 300g for 10 minutes, supernatant discarded, and the cell pellet 
resuspended in fresh media. A further two washes were carried out before the pellet 
was finally resuspended in 10 ml of growth media checked for viability via trypan blue 
and transferred to a 25 cm2 flask (Fisher Scientific, Loughborough, UK, cat. TKV-123-
011R) and incubated in an incubator at 37ºC. After 48-96 hours, cells were generally 
confluent and could be passaged and prepared for subsequent experiments. 
2.13.5 Storage of Cell Lines in Liquid Nitrogen  
Early passage number cells were divided into aliquots of about 106 cells per ml and 
stored in a liquid nitrogen dewar cylinder. Standard storage procedures used were that 
of the European Collection of Cell Cultures (ECACC, Centre for Applied Microbiology & 
Research, Salisbury, Wiltshire, England).  
 
Cells passaged from culture were washed and adjusted to 3x106 cells per ml in growth 
media containing 10% dimethylsulphoxide (DMSO) (Sigma, UK, cat. D5879) and 50% 
foetal calf serum. The cells were then divided into aliquots of 1 ml in polypropylene 
cryovials (Corning, UK, cat.430658 or 430659) and placed in a ‘Mr Frosty’ cryo-
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container (Nalgene, US, cat. 5100-0001) and then immediately placed in a -80°C 
freezer. After 24 hours in a -80°C freezer the cryovials containing cells were transferred 
to a rack in a liquid nitrogen dewar. 
2.14 Mutation Analysis using DxS TheraScreen Kits for EGFR, KRAS, 
BRAF and PI3K 
The TheraScreen mutation analysis kits (DxS Ltd, Manchester, UK) utilizes two 
technologies: amplification refractory mutation system (ARMS) and Scorpions for 
detection of mutations in Real-Time PCR. The high sensitivity and specificity provided 
by the combined primer-probe leads to the detection of a low percentage of mutant 
DNA in a background of wild type genomic DNA. Each kit includes a control assay 
alongside its corresponding mutation assays. 
2.14.1 ARMS  
The amplification refractory mutation system (ARMS) discriminates between the 
mutation and wild-type DNA by selectively amplifying the mutated target sequence 
located at the 3’-end of the primer. In the presence of targetable mutant DNA the 
ARMS primer will hybridise and be extended by Taq DNA polymerase. This results in 
the generation of detectable PCR product.  
2.14.2 Scorpions 
The detection of the amplified mutated DNA is performed using Scorpions. The 
Scorpion primer is held in a hairpin loop conformation by complementary stem 
sequences of around six bases which flank a probe sequence specific for the target of 
interest (228). In this conformation the fluorescent reporter dye (attached to the 5’-
end) is in close proximity with a quencher molecule and so no signal is produced. 
Following PCR, extension and the subsequent denaturation and annealing steps, the 
hairpin loop unfolds and if the correct product has been amplified the probe sequence 
binds to the specific target sequence on the newly synthesized strand. Since the 
fluorescent dye is no longer in close proximity to the quencher a fluorescent signal is 
generated (229).  
 
All procedures were carried out in accordance with manufacturers’ guidelines and 
standard operating procedures in use in the Queen Alexandra molecular pathology 
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diagnostic laboratory. Copies of manufactures guidelines can be found in Chapter 8.3: 
electronic appendices EGFR/KRAS/BRAF/PI3K Therascreen. 
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Chapter 3 -  Technical Development 
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3.1 Introduction 
3.1.1 Adaptation  
Cellular adaptation has been shown to occur within hours of drug exposure (78). Cells 
respond to the stress induced by chemotherapeutic agents and induce changes to 
either promote resistance or cellular death. Mechanisms involved in resistance to 
chemotherapy usually involve up-regulation of resistance mechanisms, or down-
regulation of target genes. To study these changes array technology was considered. 
3.1.2 TaqMan Low Density Arrays 
The study of cancer genetics and signalling pathways is not novel, but its importance 
now ranges from how we identify tumours to how we treat them and is constantly 
adapting to advances in molecular techniques. Single genes or proteins are unlikely to 
be looked at in isolation, unless they happen to be the specific targets to the drugs 
studied. It is for this reason that array technology has begun to prosper allowing multi-
gene signature studies. Instead of screening very large numbers of genes using 
hybridization arrays to generate signatures, the approach used here was hypothesis-
driven. Using current knowledge of the pathways involved in drug resistance and 
sensitivity a set of candidate genes was generated (Table 5). These targets are specific 
to areas of known interest in cell proliferation and differentiation, drug pumps and 
detoxification, DNA damage and repair, apoptosis as well as others targets specific to 
cell and common drug types. Through analysing these multiple targets it was believed 
that a more complex profile of tumour sensitivity could be established. These array 
data along with in vitro cellular assay data were expected to provide a better 
understanding of how tumours adapt to chemotherapy in the initial stages; looking 
particularly at tumour sensitivity, cellular stress and ultimately resistance or cell death. 
 
The Applied Biosystems (ABI) custom TaqMan arrays require minimal amounts of 
sample and allow for 4 samples to be run in parallel against 96 candidate genes and 
controls. Accuracy is insured as the arrays do not require liquid-handling robotics or 
complex pipetting to load samples, while the sealed wells decrease the risk of 
contamination. The custom assays with specific gene targets are delivered preloaded 
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and dried in microfluidic card formats and individually wrapped and barcoded to 
ensure no human errors in labelling. 
 
Each individual well of the array houses an individual real time PCR reaction. Real time 
PCR is based on the detection of fluorescence produced by a reporter molecule while 
the PCR reaction is taking place (Figure 8). The amount of fluorescence increases as the 
reaction proceeds due to the accumulation of the PCR product with each cycle of 
amplification. This method has many advantages over other traditional methods, 
including greater precision and sensitivity, numerical results and no post PCR 
processing. TaqMan probes contain a reporter dye and a non-fluorescent quencher. 
While the probe is intact the close proximity of the quencher to the reporter dye 
results in fluorescence suppression (230). Fluorescence from the reporter is only 
released when the two dyes are physically separated via hybridization or nuclease 
activity. The measurement output is the threshold cycle (Ct). It is the intersection 
between the amplification curve and the threshold line and determines the relative 
amount of cDNA starting template found in each sample. The cycle threshold is 
determined as the cycle in which the first detectable significant increase in 
fluorescence is detected. After each PCR cycle the amount of DNA theoretically 
doubles, so samples that differ by a factor of 2 would be expected to be 1 cycle apart 
and samples that differ by a factor of 10 would be approximately 3.3 cycles apart. 
 
Each TaqMan gene expression assay on the array is given an assay ID number (supplied 
by the manufacturer (electronic appendices 8.3: TaqMan Array Card Map)) consisting 
of a 2 letter prefix designating the species for which the assay was designed (Hs = 
Homo sapiens) as well as a 2 letter suffix designating the assay placement (Table 6). 
For example, the TaqMan gene expression assay for human PBGD is: Hs00609297_m1, 
indicating that this is a human multi-exonic gene assay that does not detect genomic 
DNA. 
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Figure 8: Real Time PCR reaction (adapted from applied Biosystems Real-Time PCR 
systems). 
 
Table 6: TaqMan gene expression assay placement nomenclature: The alphabetical 
suffix of the assay ID designates assay probe placement and sensitivity. 
3.1.2.1 Housekeeping Genes 
Housekeeping genes serve as a common denominator to which target gene expression 
can be normalized. A suitable housekeeping gene should be adequately expressed in 
the tissue of interest, and show minimal variability in expression between samples, 
under experimental conditions. Therefore, housekeeping genes are chosen from genes 
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that are always expressed because they code for proteins that are constantly required 
by the cell and most likely present under any conditions.  
 
The identification of stable housekeeping genes for real time RT-PCR is a critical 
requirement for both accurate and meaningful analysis of target gene expression. 
Fluctuations in housekeeping gene expression can result in misrepresentation of 
differences in target gene expression. Obtaining reliable measurements depends on 
the choice of control genes which is achieved by selecting relevant stable 
housekeeping genes (231, 232). Five housekeeping genes were chosen for the array 
(Table 5) allowing the most suitable gene for the sample data to be used for 
standardisation.  
 
Control cDNA made from a cocktail of human tumour samples were used to test inter 
and intra assay variability (Electronic Appendices -8.3: Control cDNA repeats). The 
control cDNA was also used to test operator and climate variability (samples run at 
varied points throughout the day). These tests included three operators running assays 
over three days at varied times. This gave rise to a coefficient of variation value for five 
repeats over three days being less than 3% when Ct values were available. 
3.1.2.2 Data Transformation, Standardisation and Normalization  
Normalization refers to the division of data by a common variable in order to cancel 
out that variable's effect on the data.  
 
Data was analysed using a new method formulated with help from statisticians from 
Applied Biosystems (Foster City, San Francisco, US). The cycle number is first converted 
to presumed copy number (i.e. 2-Ct) assuming similar primer efficiencies. This allows 
the gene expression ratios to be taken without skewing the data. It is then 
standardised against the best housekeeping gene for that data series (i.e. 2-Ct(test)/2-
Ct(PBGD)). Data is then transformed by natural log transformation of this value, (i.e. Ln(2-
Ct(test)/2-Ct(PBGD))) giving the data a normal distribution.  
 
Due to the design of the arrays it was not possible to use an efficiency corrected 
method (relative standard curve method) when normalizing data. The array cards only 
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hold positions for 4 samples per card meaning only a 4 point standard curve could be 
carried out. In this instance the gene expression ratio (GER) method was more 
appropriate. 
3.1.3 Sequential Therapy  
When carrying out a standard ATP-TCA it is possible to test drug combinations as well 
as single agent activity. To test drugs in sequence a new assay needed to be 
developed. Knowing that the limitation to any chemosensitivity assay, molecular or 
cellular, was that it was only as good as the drugs that are available, much thought 
needed to be taken in choosing which drug sequences to study. Unfortunately, 
cytotoxic chemotherapy is not good enough to provide a cure for every patient. This 
almost certainly reflects the biology of the tumour and the adaptability of neoplastic 
cells to drug exposure. Therefore, overcoming this adaptation will inevitably be a 
challenge. By looking at the mechanisms involved in cellular adaptation, resistance and 
re-growth it may be feasible to see trends in the way tumour cells adapt to certain 
types of chemotherapy to which new scientifically guided sequential regimens can be 
developed to utilise this information. 
3.1.4 High Throughput Drug Screening  
As advances in cancer screening and earlier tumour detection continues, the amount 
of fresh tumour material available for research declines. If cellular assays are to 
continue they must be adapted to use fewer cells. Moving these 96 well assays from 
96 to 384 well footprints would be the most logical step forward as long as both the 
variability and reproducibility continued to produce the same consistent results as the 
original 96 well assays. Manual pipetting with 384 well plates using relatively small 
volumes is time consuming and often imprecise due to human error. It would 
therefore be more beneficial to use an automated liquid handling system such as the 
Janus Modular Dispense Technology (MDT) with the addition of a 96 well head and 
serial dilution tool (Perkin Elmer, Seer Green, UK). 
 
The development of anticancer agents commonly relies on screening potential drugs 
against cell lines. These however, show significant differences in their behaviour from 
tumour-derived cells in primary cell culture or xenografts. Nevertheless, cell lines 
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continue to be used because of their convenience and utility for high throughput 
screens. Cell line models do have their uses: for instance isogenic cell models (Horizon 
Ltd, Cambridge, UK) have been generated with a parental line and subsequent lines 
that include specific isogenic mutations. These cells would be useful for the 
development for specific molecularly targeted drugs where targets fall in mutated 
regions. 
3.2 Methods and Results TaqMan Low Density Array (TLDA) 
Many published studies on cellular adaptation and resistance to anti-cancer drugs have 
investigated the development of resistance using cell lines generated in the lab after 
prolonged and step-wise exposure to anti-cancer drugs.  While this approach provides 
cells with acquired resistance, these cells do not represent the true nature of the in 
vivo situation, where patients are administered chemotherapy cyclically over a period 
of weeks. Results from this study have shown the limitations on reproducibility when 
using cell lines to study expression changes in stress responses (Figure 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Loss of gene expression in the ovarian cell line JAMA2 during 6 weeks in cell 
culture showing an overall relative decrease from 1 to -1 equating to 4 times the 
cDNA product. 
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A change in the gene expression of the ovarian cell line JAMA2 has shown to occur in 
as little as 6 weeks (passaging at once a week intervals). While this loss is seen 
throughout many of the genes tested the remaining housekeeping genes not used for 
standardisation remained relatively stable (Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Stability of remaining housekeeping genes in the ovarian cell line JAMA2 in 
culture over 6 weeks when standardised to PBGD. 
Duplicate flasks of cells from the same passage, harvested and exposed to 2.5 µM 
cisplatin simultaneously showed a difference in adaptation to some genes tested 
(Figure 11). This suggests that cell lines that were originally derived from single clones 
could utilise different cellular adaptation mechanisms when subjected to the same 
stress inducing factors. As signal transduction usually involves multiple steps there is 
opportunity for diverse pathway branching and cross-talk to occur. 
 
Differences in gene expression from multiple cell line experimentation could also result 
from confluency at cell harvest. This could account for differences seen in proliferative 
genes where overcrowding can promote apoptosis or senescence (233). Gene 
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expression may also alter in over confluent cells due to contact and nutrient inhibition 
(234, 235). Alteration in signalling pathways has also been observed with respect to 
culture media, where differences in biologically relevant pathways are seen between 
culture in DMEM and MEM (236).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Heterogeneity of JAMA2 cell line response to gene expression when cells 
were treated simultaneously 
Increasingly some studies have demonstrated that over-subculturing cell lines change 
their properties over time (237-243). It is important to ensure reliable and 
reproducible results so where cell line models must be used it may be useful to avoid 
the use of cell lines that have been in culture too long. Primarily cells that are in 
culture are under stress from being in an ‘alien’ environment. The stress of culture 
creates pressure for cells to adapt and evolve giving rise to situations favourable to 
genotypic and phenotypic changes. As cells continue to grow and are subcultured 
these changes accumulate giving rise to a line of cells so far removed from their 
original patient origin that they no longer function like their in vivo counterparts (227).  
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It is for these reasons that where possible, tumour cells derived directly from patients 
were used for these studies, reducing the amount of manipulation and culturing prior 
to experimentation.  
 
3.3 Methods and Results ATP – Sequential Assay (ATP-TSCA) 
The translation of the ATP-TCA from the current format to include testing for 
sequential chemotherapy regimens is designed to give more information on the 
interaction between the tumour sample and/or the different drugs used. At the start 
of these studies, many methodologies were tried and tested. The initial experiments 
used ovarian cell lines (JAMA2) as opposed to tumour derived cells, given they were 
readily available in large cell quantities and being homogenous would hopefully 
provide greater reproducible results.  
 
In addition to testing a number of molecularly targeted agents, it was the intention to 
test representatives of all major cytotoxic drug classes, both cycle-specific and non-
cycle dependent type. Experiments were carried out with cells originating from 
tumours where drugs already had an established use (e.g. the use of lung cell lines in 
gefitinib treatment). Initial experiments carried out with the ovarian cell line JAMA2 
were approached by looking back at ATP-TCA results obtained over the previous six 
years (79). It was observed that the most efficient combination following failure of first 
line platinum treatment was the combination treosulfan plus gemcitabine. As much 
data on this drug combination existed in the labs’ database, this was the first sequence 
used to test the efficiency of the new sequential assay. 
 
Cells were grown to between 80-95% confluence in either 25 cm2 or 75 cm2 (Sigma, 
UK, cat: CLS3289, CLS3290) cell culture flasks. In these initial experiments two identical 
flasks were seeded. Once at confluence, culture media was discarded and the flasks 
washed with 2 ml PBS (Sigma, UK, cat: D8537). Either 15 ml CAM or 15 ml CAM 
supplemented with cisplatin was added to the culture flasks. These were incubated at 
37°C and 5% CO2 for 24 hours before being passaged and cells plated according to the 
standard ATP-TCA protocol (Chapter 2.13.3 Passaging Cell Lines, Chapter 2.2.8 
Preparation of 96 Well Plates). 
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Pre-incubation times were initially taken from observations from Di Nicolantonio et al. 
(78) who saw changes in cellular response occurring within 24 hrs of drug exposure. 
The ATP-TCA assay is optimal over a 6 day period therefore, consideration for pre-
incubation times followed by sufficient time for second drug exposure and subsequent 
cell death needed to be factored into the design. Standard (100% Test Drug 
Concentration (TDC)) concentrations of the initial drug in the sequence were not used 
for all drugs, as the idea of the sequential assay was to determine whether preliminary 
drug exposure could render tumour cells more susceptible to second agents. Thus pre-
exposure with a concentration of cisplatin designed to induce a cellular response and 
not cell death was required. This was devised from results obtained from standard 
ATP-TCA results from 379 ovarian tumours (Figure 12). A concentration in which 
roughly between 10 and 20% (2.5 µM) tumour growth inhibition was achieved over 6 
days was considered suitable to promote cellular adaptation within 24 hours at both 
ends of the sensitivity spectrum. This also took account for the overall increase in 
sensitivity associated with cell lines in long term culture (243). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Heterogeneity of ovarian tumour derived cells (n=379) to cisplatin (error 
bars indicate the most and least sensitive tumour while the blue series shows mean 
cisplatin sensitivity). 
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Results from the sequential assay shown in Figure 13 showed increased resistance to 
gemcitabine and its combination with treosulfan when cells were pre-exposed to 
cisplatin. However, treosulfan showed an increased sensitivity at lower concentrations 
when pre-exposed to cisplatin for 24 hours. 
Figure 13: Sensitivity of the cell line JAMA2 to treosulfan and gemcitabine alone, in 
combination and with 24 hour pre-treatment with 2.5µM cisplatin. With cisplatin 
pre-treatment carried out in culture flasks 
 
This experiment showed that a sequential assay was possible although it would need 
to be adapted further to be suitable for use with tumour-derived cells which would not 
be cultured in flasks. The pre-incubation step was therefore adjusted to take place in 
96 well plates (Figure 14). These parameters were then tested in parallel with JAMA2 
cells both pre-incubation in flasks and pre-incubation in 96 well plates before the 
addition of the second drugs (Figure 15). Pre-incubating the drugs in the plates prior to 
the addition of the second drug combination produced less erratic results, however 
the general cell sensitivity was greater. This could be due to the lack of stress which is 
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caused by passaging the cells with trypsin and removing them from the flask before 
plating in the sequential assay, or that the cell seeding density exposed to cisplatin 
could be more accurately defined.  
 
To ensure that the activity shown in the 96 well pre-incubation assay was due to the 
sequence in which the drugs were administered and not synergy of the combination, a 
wash step was added. This eliminated traces of the preliminary drug from the media 
and ensured the effect seen was due to the adaptation brought on by the first drug 
followed by the subsequent effect of the addition of the second drug. 
Figure 14: Sensitivity of the cell line JAMA2 to treosulfan and gemcitabine alone, in 
combination and with 24 hour pre-treatment with 2.5µM cisplatin. With cisplatin 
pre-treatment carried out in culture plates. 
 
Time course experiments were carried out to ascertain if there was an optimum time 
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specific targets. These involved testing agents such as gefitinib and cetuximab 1-6 days 
post 24 hr cisplatin exposure (see adaptation chapter, page 89: Figure 30 - Figure 34).  
Results were then compared with molecular data obtained using TaqMan low density 
array’s to determine the level of expression of apoptosis, proliferation and resistance 
mechanism associated genes during this time. 
Figure 15: Sensitivity of the cell line JAMA2 to gemcitabine alone, in combination 
with treosulfan and with 24 hour pre-treatment with 2.5µM cisplatin. With 
comparison of cisplatin pre-treatment carried out in flasks and in culture plates. 
 
The lack of response of cells to second agent chemotherapy may be explained by a 
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(EGF) was used to try to promote tumour re-growth normally occurring in vivo, so that 
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treated, single agent or sequential treatments in the cell lines tested (Figure 16). A 
switch to lung cancer cell lines was due the fact that gefitinib had been licensed for use 
in NSCLC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16:  Sensitivity of NCI-H23 lung cancer cells (which does not harbour an EGFR 
mutation) to single agent and sequential cisplatin and gefitinib with and without EGF 
supplement 
3.4 Methods and Results ATP – High Throughput Assay (ATP-THCA) 
Using 384 well plates and the ATP-TCA based cell assay, high throughput screening of 
agents with unknown or possible anticancer properties using primary cell cultures was 
devised. Custom programs were designed and created for the Janus MDT (Perkin 
Elmer, Seer Green, UK) using its 96 tip head and serial dilution tool to increase 
accuracy and reproducibility. 
 
Initial programs were designed to test the growth capabilities of different volume 384 
well plates. These plates were chosen to mimic the ATP-TCA 96 well plates as closely as 
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possible. Therefore, plates were chosen with round bottoms in polypropylene ensuring 
cells would not adhere to the surface of the plates. This also ensured that when 
tumour derived cultures were used the plates would not support the growth of non-
neoplastic cells.    
 
Deep Well Plates (Greiner, Gloucestershire, UK, cat. 781271) incubated with 100 µl 
CAM were compared with shallow well plates (Corning, UK, cat. 3656) incubated with 
40 μl CAM at 5000 cells per well (densities obtained from previous studies (246)). 
Results (Figure 17) indicated that cell survival was greater in the shallow plates (MO 
average 514 relative light units (RLU) in deep well versus 1497 RLU in Shallow Well). 
This is probably due to better gas exchange in the shallow plates which had a higher 
surface area to volume ratio.  Shallow well plates were therefore used for all 
subsequent work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Comparison of relative light units for media only wells in deep and shallow 
well plates. 
The volume of tumour cell extraction reagent (TCER) used to lyse cells and the cell 
lysate to luciferin-luciferase (LuLu) volume ratio added to white plates following the 
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the results. In the higher volume deep well plates the ATP concentration might have 
been diluted by the addition of a higher volume of the extraction reagent, giving rise to 
lower than expected ATP values.   
 
Six plates were set up with varying volumes of TCER and varying ratios of tumour 
lysate to LuLu. These experiments were conducted with 2,500 cells per well of an 
ovarian ascites sample from which sufficient cells were available to assess the 
optimum volumes used in the white plates to measure ATP levels. These were 
compared over both a 5 and 6 day incubation period.  
 
Index sum variation for the cytotoxic drugs tested was relatively low over all 4 plates 
read at the 5 day incubation period (coefficient of variation (CV) all below 20%), shown 
for cisplatin in Table 7. However, the higher RLU values seen with the 20 μl:20 μl cell 
lysate to LuLu ratio produced better results with greater MO values giving rise to 
better variance results. No great difference was seen with the different TCER volumes, 
however again the greater RLU value was seen in those with 5 μl volumes, suggesting 
that this is enough reagent to lyse the cells and not dilute the ATP content (Table 7).   
Table 7: Intra-assay variability of cisplatin in 384 Shallow plates with various TCER 
and Lulu volumes 
 
Those plates read on the 6th day of incubation produced slightly erratic results with a 
media only CV of 88% (Table 8). These were located in the bottom edge of the plate 
showing a range of 276-2698 relative light units (RLU). It was observed that during this 
6 day incubation period evaporation of media at the edges of the plates occurred. This 
left some wells with less than 40 μl total volume before ATP extraction. Due to this 
phenomenon any single well assays using the entire 384 well plate will need to be 
performed with a 5 day incubation period or exclude the outer wells from use. 
Drug
TCER 
Volume 
(μl)
Lulu 
Volume 
(μl)
Index SUM  
plate 
triplicate 1
Index SUM  
plate 
triplicate 2
Index 
SUM CoV 
(%)
Mean MO 
(RLU)
MO         
CoV (%)
Cisplatin 5 10 206 285 16% 819 44%
Cisplatin 10 10 248 310 11% 1395 21%
Cisplatin 5 20 469 498 3% 1995 44%
Cisplatin 10 20 326 431 14% 1177 26%
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Comparison of 384 well shallow plates with the original 96 well plates showed that the 
downscaling of the ATP-TCA from 96 to 384 wells was successful (Figure 18-Figure 20). 
This method as well as being useful for tumours with limited cell numbers would be 
useful for screening large numbers of drugs. 
Table 8: Raw data showing relative light units (RLU) from a 384 Well plate 6 Day 
incubation of an ATP-THCA (Media only wells in bold at bottom of plate) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Comparison of cisplatin sensitivity in the ATP-TCA and ATP-THCA assays 
0 0 0 3 0 0 2 0 0 3 0 0 2 1 2 0 0 0 0 0 2 0 1 1
274 138 119 11 5 18 0 0 0 0 0 0 0 17 0 0 0 0 57 106 80 2 1 3
185 86 211 6 0 3 8 0 4 0 0 0 31 4 14 0 28 5 319 76 160 0 1 0
370 307 330 37 28 17 2 6 7 0 0 0 173 284 161 197 149 167 516 436 369 23 14 0
365 465 343 19 36 70 16 10 27 2 15 5 197 358 358 323 217 98 522 239 587 3 22 8
510 339 563 162 120 181 26 123 77 90 339 155 446 915 750 476 409 333 855 644 751 86 63 33
361 181 458 156 135 202 104 120 229 350 732 550 300 337 464 593 406 229 587 454 731 39 36 47
108 103 214 2 4 4 3 3 0 3 0 3 6 0 2 0 0 1 154 82 117 15 9 2
239 194 330 13 20 4 0 0 1 0 0 10 74 29 41 1 64 12 227 113 256 7 2 0
612 413 681 22 56 55 16 2 16 3 6 2 182 147 168 249 168 121 442 411 274 5 7 0
428 330 396 30 122 36 47 5 11 4 16 0 103 74 196 109 145 66 565 259 562 0 32 0
526 1134 760 182 120 246 44 230 69 111 170 238 641 305 227 425 474 326 610 827 834 34 16 49
235 390 663 89 345 67 410 338 91 163 722 134 57 137 825 88 302 106 1027 121 210 24 58 878
425 428 613 668 436 510 634 1490 786 389 341 344 386 345 388 385 316 339 276 284 504 370 434 2698
Paclitaxel 
Paclitaxel + 
Cisplatin 
Treosulfan 
Tresulfan + 
Gemcitabine 
Cisplatin Gemcitabine 
Cisplatin + 
Gemcitabine 
Doxorubicin 
x3 
BLANK WELLS
Paclitaxel 
Paclitaxel + 
Cisplatin 
Treosulfan 
Tresulfan + 
Gemcitabine 
Cisplatin Gemcitabine 
Cisplatin + 
Gemcitabine 
Doxorubicin 
x3 
0
10
20
30
40
50
60
70
80
0.63 1.25 2.50 5.00 10.00 20.00
P
e
rc
e
n
ta
ge
In
h
ib
it
io
n
 (
%
)
Cisplatin (µM)
Sensitivity of a Recurrent Ovarian Tumour to Cisplatin 
in different plate volumes
384 Well Plate 96 Well Plate
78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Comparison of cisplatin sensitivity in the ATP-TCA and ATP-THCA assays 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Comparison of paclitaxel sensitivity in the ATP-TCA and ATP-THCA assays 
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3.4.1 ATP-THCA for use in Screening Large Compound Libraries 
A large library of 5605 plant extracts was obtained (Strathclyde Institute for Drug 
Research (SIDR), University of Strathclyde, Glasgow, UK). Each extract was screened in 
3 recurrent ovarian tumours and inhibitory effects calculated by percentage inhibition. 
Cells were isolated from fresh tumour samples. These were incubated with 12.5 µg/ml 
drug compound for 5 days in 384 well polypropylene plates (352 compounds per plate) 
before being lysed and ATP levels measured by luciferin-luciferase assay. This assay 
was performed using the Janus MDT liquid handling robot with a 96 well tip head and 
serial dilution tool (Perkin Elmer, Seer Green, UK). 
 
There were 113 positive hits for sensitivity (Electronic Appendices 8.3: SIDR Single well, 
high through put screen); these were classified where greater than 80% inhibition was 
achieved in all 3 tumour samples. These positive hits were then tested further for 
luciferase inhibition to rule out any compounds inhibiting the assay’s detection system. 
 
Luciferase sensitivity plates were setup with 40 µl of the 12.5 µg/ml extract added to 
an 83.33 ng/ml ATP solution (10µl/well) in a 96 well white plate (Thermo Life Sciences, 
UK, cat. 7905). 50 µl of Luciferin-luciferase was then added before reading in a 
luminometer. From this screen 33 extracts were excluded due to their incompatibility 
with the luciferin-luciferase assay (Electronic Appendices 8.3: SIDR Luciferase assay).  
 
The remaining 80 extracts were then tested again in a further 3 recurrent ovarian 
tumour samples; over 5 drug concentrations in triplicate (14 extracts per plate). 
Alongside these extracts 4 combinations of known cytotoxics were tested, examples of 
these can be seen in Figure 21 - Figure 23 (Full 80 extract data; Electronic Appendices 
8.3: SIDR Dilution Screen). Plate layouts were designed so that blank wells were left at 
either side of the plate compensating for any evaporation (Technical development 
Chapter: 3.4). Extracts that had previous activity but whose activity had now 
diminished, were now excluded (n=33). This was probably due to extract instability 
caused by multiple freeze thaw actions associated with prior experimentation. While 
this did not necessarily exclude the extracts for their sensitivity any extract to be taken 
80 
 
further for drug development would need to be stable past a few freeze thaw actions 
required for testing, as well as possible future drug manufacturing and dispatch.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Sensitivity of 3 recurrent ovarian tumours to treosulfan + gemcitabine in 
the 384 well high throughput screen 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Example of sensitivity of 3 recurrent ovarian tumours to a plant extract in 
the 384 well high throughput screen (example 1) 
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Figure 23: Example of sensitivity of 3 recurrent ovarian tumours to a plant extract in 
the 384 well high throughput screen (example 2) 
3.5 Discussion 
The continued development of pre-existing assays to incorporate sequential and small 
volume high throughput methodologies has been successful. The combined data with 
that of the TaqMan array technology will inevitably provide a more detailed picture of 
tumour cell response and adaptation to therapy.   
 
TaqMan array data has already been shown to be well suited to investigate the 
presence of resistance mechanisms in ovarian, lung and melanoma cancers alongside 
cellular chemosensitivity testing and clinical results (208-210). It also has many 
benefits for future use as it requires only small fragments of tumour tissue which can 
be obtained from archived formalin fixed paraffin embedded specimens as well as 
fresh tissue. This can allow for large retrospective studies from pre-existing clinical 
drug trials in which patient outcome is already known.  
 
The adaptation of the standard ATP based tumour chemosensitivity assay to include 
testing of sequential regimes will be evaluable for study presented in this thesis. Its 
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application in studying how cells adapt to changes in chemotherapy will also improve 
understanding of drug scheduling (continued in Chapter 4 - Adaptation and Chapter 7 - 
Targeting the Mevalonate Pathway). However, the potential use of results generated 
from low dose drug exposure in this type of assay in predicating any clinical 
significance is not clear, as these agents would not be used in patients at these 
concentrations. Heterogeneity of dose escalation response to platinum agents is 
evident and so this type of assay may therefore be more suited to targeted agents or 
drugs with cytostatic responses, where cells could be pre-exposed to drugs in similar 
concentrations to those seen in vivo. 
 
The development of 384 well cell assay applications allowed for development of a 
novel screening approach for large libraries of potential anti-cancer compounds. This 
design enables large numbers of agents to be tested against tumour-derived cells 
where previously the cell numbers required for such studies could not be achieved 
without the use of cell lines. Collaborative studies with SIDR continue, with further 
development to discover active fractions of the positive compound hits found here. 
Further use of this 384 well platform is continued in Chapter 5 - Cisplatin and RAS 
Effector Inhibition, where this assay was used to study drug combinations at multiple 
concentrations in a checkerboard style pattern.  
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Chapter 4 -  Adaptation 
84 
 
4.1 Cellular Adaptation to Chemotherapy 
Oncologists have long been studying how tumours adapt to first line chemotherapy by 
observing how effectively patients respond to subsequent treatment. This has helped 
shape the way standard regimes for particular tumours have developed. Cancer cells 
can start adapting to anti-cancer agents within 24 hours (78); so the potential to 
exploit common adaptation results early on could lead to a more defined, molecular 
driven target based regime design. This could give rise to possibilities for greater 
enhanced sensitivity for second-line, sequential or maintenance therapies. 
 
Figure 24: Downstream receptor tyrosine kinase signalling (e.g. EGFR) including 
relevant targets found on the TaqMan gene expression array and important for cell 
survival, proliferation, protein synthesis and angiogenesis. 
85 
 
Cisplatin kills cancer cells by damaging DNA and inhibiting DNA synthesis and is one of 
the most widely used drugs for first line cancer treatment, particularly for lung and 
ovarian cancers. How cells respond to cisplatin-induced DNA damage determines 
cisplatin sensitivity (53). For these reasons cisplatin is the most logical drug to look at 
with regards to adaptation and sequential therapy strategies.  
 
EGFR and its downstream signalling pathways have been identified as being associated 
with cisplatin sensitivity. Cisplatin has also been shown to stimulate internalisation of 
EGFR and activate downstream signals involving p38, PI3K and AKT (247, 248). Intrinsic 
intracellular protein-tyrosine kinase activity brought about by EGFR leads to activation 
of multiple downstream signal transduction pathways shown in the simplified diagram 
in Figure 24. In addition, EGFR inhibitors have been useful for patients who failed 
cisplatin-based therapy, but less effective when administered in combination. Poor 
combination effects are thought to result from gefitinib interfering with cisplatin entry 
into cells (104, 247, 249, 250).  
 
Effects of cisplatin on the EGFR pathway remain unclear, but the potential role for 
sequential treatment makes it an important starting point to examine (251).  
4.2 Results 
4.2.1 Single Agent Sensitivity 
Tumour derived cells (n=19) from 8 melanomas, 6 lungs, 3 ovarian and 2 other solid 
tumours were tested for their sensitivity to gefitinib. Cellular sensitivity showed some 
heterogeneity in its response to gefitinib. However, resistance (IndexSUM >350) was 
seen in 89% (17 of 19) of tumours tested. All tumours and cell lines tested for 
sensitivity to cetuximab showed resistance with an IndexSUM >400. 
4.2.2 Sequential Assay 
Using the sequential assay (Chapter 3.1) tumour derived cells were tested for their 
sensitivity to gefitinib alone compared with sensitivity to gefitinib following 24 hr 
cisplatin pre-exposure (2.5 µM). Single agent gefitinib showed a trend for resistance 
with IndexSUM results ranging between 315 and 646. Sequential results with 2.5 µM 
cisplatin pre-exposure showed little change in sensitivity (Figure 25). The exception to 
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this was four tumours of differing origin, a cisplatin resistant recurrent ovarian tumour, 
a cutaneous melanoma, a pancreatic tumour and a squamous cell lung carcinoma 
(donated prior to routine mutation analysis and therefore EGFR mutation status for 
this tumour is unknown). These tumours showed greater gefitinib activity when pre-
treated with cisplatin and examples of their sensitivity can be seen in Figure 26 - Figure 
29. However, cellular inhibition in these tumours did not exceed 60%, with only the 
ovarian tumour producing a sensitivity index of less than 300 (IndexSUM =269) 
considered sensitive.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Effect on 19 individual tumours from differing origin with gefitinib alone 
and sequentially with low dose cisplatin (Pre-exposure for 24Hrs), showing an 
increase in sensitivity (reduction in IndexSUM) of some tumours when pre exposed to 
cisplatin (2.5 µM). 
0
100
200
300
400
500
600
700
800
Gefitinib Gefitinib (Pre-Treatment Cisplatin)
IN
D
EX
SU
M
Drug Treatment
The effect of Gefitinib alone and sequentially with low dose 
Cisplatin  on Tumour derived cells
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Sensitivity of a recurrent ovarian tumour to gefitinib alone, in combination 
and in sequence with low dose cisplatin 2.5 µM (Pre-exposure 24Hrs) 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Sensitivity of a melanoma tumour to gefitinib alone, in combination and in 
sequence with low dose cisplatin 2.5 µM (Pre-exposure 24Hrs) 
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Figure 28: Sensitivity of a pancreatic tumour to gefitinib alone, in combination and in 
sequence with low dose cisplatin 2.5 µM (Pre-exposure 24Hrs) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Sensitivity of a squamous cell lung carcinoma to gefitinib alone, in 
combination and in sequence with low dose cisplatin 2.5 µM (Pre-exposure 24Hrs) 
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4.2.3 Sequential Assay and Cellular Recovery 
Gefitinib sensitivity could be enhanced in both cell lines and tumour derived cells 
where previously no increase in sensitivity was observed. This was achieved when a 
recovery period was introduced between primary cisplatin exposure (2.5 µM) and the 
serial dilution of gefitinib (Figure 30 - Figure 32). This phenomenon could also be 
repeated with another EGFR inhibitor, cetuximab (Erbitux) (Figure 33, Figure 34). 
Although sensitivity was shown to be increased in these samples, this increase was still 
not enough to put the indexSUM marker of sensitivity below 300, considered to reflect 
clinical sensitivity (175).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Sensitivity of the lung cancer cell line NCI-H23 to gefitinib given over a 
delayed time course following 24 Hrs cisplatin treatment  
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Figure 31: Sensitivity of the oesophageal cancer cell line OE19 to gefitinib given over 
a delayed time course following 24 Hrs cisplatin treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Sensitivity of an ovarian tumour to gefitinib given over a delayed time 
course following 24 Hrs cisplatin treatment 
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Figure 33: Sensitivity of the oesophageal cancer cell line OE19 to cetuximab given 
over a delayed time course following 24 Hrs cisplatin treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Sensitivity of a lung adenocarcinoma to cetuximab given over a delayed 
time course following 24 Hrs cisplatin treatment 
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4.2.4 Downstream RTK Gene Expression targets and sensitivity to gefitinib 
Material for gene expression analysis was available in 47% of samples (9 of 19). This 
sample size was unfortunately too small to make any statistical claims; however, gene 
expression of targets downstream and including growth receptors showed some 
heterogeneity in expression levels. The gefitinib sensitive ovarian tumour (Figure 26) 
showed relatively elevated expression of EGFR, HER2 and HER3 receptors and lower 
expression of receptors IGFR1/2, survival targets Bcl-2 and p53 and proliferation 
targets p21 and p27 when compared with more resistant tumours (Figure 35).  
Figure 35: Waterfall plots of 9 tumours (Labelled O-ovarian, L-lung and S-skin 
melanoma) showing increasing resistance (bar chart) to cisplatin and gefitinib alone 
and in sequence with relation to their pre-treatment relative gene expression 
(standardised to PBGD) of growth factor receptors and downstream targets 
(highlighted green and red for the greatest and least expression)  
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4.2.5 Sequential Gene Expression and Mutation analysis 
Material for sequential gene expression analysis (9 of 19) showed a trend for tumours 
to exhibit changes in expression within classes of genes involved in apoptosis and 
growth as well as inflammation, resistance and drug transport, showing the expected 
changes in gene expression for these tumours in response to cisplatin exposure (Table 
9).   
Table 9: Changes in gene expression (> 1Ct) of tumours exposed to cisplatin (2.5 µM) 
compared with drug sensitivity (IndexSUM) of cisplatin and gefitinib alone and 
sequentially (full data Chapter 8.3: Electronic Appendices- Sequential GER)  
 
There was some variation in the genes activated or suppressed between individual 
tumours and no clear distinction between tumours that were sequentially sensitive 
and tumours that were resistant.  
 
Gene expression data for the recurrent ovarian tumour which responded to sequential 
treatment with cisplatin and gefitinib (Figure 26), showed changes greater than 1 Ct 
(double/half the cDNA material) value in Cox2, MTII, PTEN and FAS (Table 9). Gene 
expression for this tumour following cisplatin exposure and tumour recovery showed a 
marked increase in PTEN expression (Table 10). Enough material was available in this 
instance for further testing for activating mutations thought to be important in 
gefitinib sensitivity (Table 13, Page 119). Results showed it to be negative for EGFR, 
KRAS, BRAF and PI3K mutations suggesting that its sensitivity was due to its gene 
expression profile rather than any of the mutations tested.  
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Table 10: Changes in gene expression of the sequential cisplatin and gefitinib 
sensitive recurrent ovarian carcinoma following drug exposure and recovery 
(comparisons made with media only/ drug free control starting point, cell exposure 
to cisplatin (24 hours at 2.5 µM) and cells exposed to cisplatin washed and left to 
recover with measurements made at 24hr increments. Full data Chapter 8.3: 
Electronic Appendices- Sequential GER) 
 
4.3 Discussion 
4.3.1 Gefitinib Sensitivity 
Gefitinib resistance was seen in 89% (17 of 19) of tumours tested which is in 
accordance with previous studies and clinical data (104). Sensitivity to gefitinib seen in 
Gene
Pathway 
Location
EGFR 1.29 1.53 1.02 1.06 0.89
HER2 1.30 1.30 1.16 1.07 1.07
HER3 0.83 1.16 0.82 1.02 0.68
HER4 -3.69 -3.96 -3.37 -3.29 -3.47
IGF1R -0.23 -0.11 -0.08 0.17 0.09
IGF2R 1.54 1.55 1.39 1.42 1.43
PIK3CA 0.71 0.49 0.39 0.60 0.51
PTEN -1.23 -2.98 -0.03 0.22 0.66
Akt 2.40 2.53 2.31 2.35 2.41
p21 1.88 1.84 1.80 2.24 2.86
p27 2.00 1.96 2.05 2.23 2.06
mTOR 1.85 1.86 1.42 1.67 1.87 Protein synthesis
HIF1A 2.87 2.98 2.77 2.83 2.38
VEGF 2.14 1.91 2.06 2.25 2.49
p53 -0.72 -0.85 -1.04 -1.19 -1.57
Bcl2 -1.64 -2.16 -2.92 -3.29 -2.78
Bax 1.67 1.60 1.36 1.83 2.07
NFkB 1.85 1.86 1.44 1.45 1.38
Bcl-x(L) 1.42 1.32 1.39 1.56 1.62
XIAP 0.63 0.60 0.07 0.18 0.22
Bad -0.83 -1.00 -0.58 -0.53 -0.33
Drug Free 
Control
24 Hr 
Cisplatin
24 Hr 
Cisplatin 1 
Day Recovery
24 Hr 
Cisplatin 2 
Day Recovery
24 Hr 
Cisplatin 3 
Day Recovery
Growth 
receptors
Intermediate 
Signalling
Proliferation
Angiogenesis
Survival
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NSCLC clinical samples has shown to be increased with the presence of activating 
mutations within the EGFR gene (115, 252, 253). The phenomenon in which EGFR 
mutations suggest possible sensitivity to anti-EGFR targeted therapy may not be 
reflected in all tumour types. EGFR mutations are found less frequently in ovarian 
(250) and  colorectal (254, 255) cancers but still show variable sensitivity to anti-EGFR 
based therapy  (251, 256-258).   
 
The increased gefitinib sensitivity following short low dose cisplatin exposure was 
independent of tumour type occurring in some tumours but not others. This suggests 
mechanistic similarities to either cisplatin exposure or gefitinib sensitivity within these 
tumours.  
 
Gefitinib has shown little clinical effect outside NSCLC EGFR mutated cancers as a 
single agent or in combinational or sequential settings (104). This intrinsic resistance 
may in some part be due to the continued cellular pathway activation via alternate or 
compensatory signalling pathways (IGFR and MET) (61, 75, 76, 259-261). Alternative 
strategies to target multiple aspects to this pathway may prove more fruitful. As by 
combining inhibitors of EGFR with alternate or continued signalling pathway targets, 
mechanisms of resistance may be circumvented. 
4.3.2 Cetuximab Sensitivity 
Sequential results for cetuximab following cisplatin exposure in oesophageal and lung 
cancer cells (cell line and primary tumour cells respectively) showed an increase in 
sensitivity when anti-EGFR antibody therapy is delayed between 1 and 3 days. These 
data also showed similar effects with the tyrosine kinase (EGFR) inhibitor gefitinib.  
 
Response to delayed schedules has also indirectly been shown within the phase II trials 
with cisplatin based chemotherapy and tyrosine kinase inhibitors (TKI’s)  in lung cancer 
patients (262, 263). The sequence employed by Zwitter et al had cisplatin given on day 
2 and the TKI erlotinib given 3 days later interspersed with gemcitabine given on days 1 
and 4. Positive results were seen for this dosing schedule but it is not clear whether 
these results were in part due to activating mutations with EGFR. 
 
96 
 
Cetuximab has been shown to sensitise breast cancer cells to cisplatin. Activity is 
thought to be achieved by cetuximab suppressing cellular DNA repair capacity, thus 
prolonging the presence of cisplatin induced DNA adducts or by increasing apoptosis 
and arresting the surviving cancer cells in the G(2)/M phases of the cell cycle (264, 
265).  
4.3.3 Gene Expression 
Sufficient material for gene expression analysis was only available in around half of the 
tumour samples and so no statistical comparison could be effectively performed. 
However, molecular data showed greatest changes in expression from cisplatin 
exposure within genes associated with drug transport, drug resistance, apoptosis, 
proliferation and growth. Adaptation within these genes look to be as heterogenic as 
the phenotypic response they induce.  
 
Ability of the EGFR inhibitor gefitinib to inhibit functions of transporter proteins (e.g. 
BCRP and MDR1) by binding at their ATP binding sites may be found to be useful in 
MDR cancer cells (266). However, the relevance here to cisplatin is minimal as this 
agent does not seem to be pumped via these proteins (267).  
 
While cisplatin treatment has been shown to activate the EGFR pathway through 
phosphorylation of AKT and ERK this has been shown to occur in the absence of ERCC1 
(268, 269). Gene expression data for those tumours with sufficient material showed 
ERCC1 to be actively expressed in all tumours tested but expression did not change 
extensively in response to cisplatin exposure (Electronic Appendices 8.3: Sequential 
GER). 
 
Cisplatin recovery experiments with the recurrent ovarian tumour sensitive to cisplatin 
and gefitinib sequential therapy continued to show minimal changes in ERCC1 gene 
expression. A similar lack of expression change was seen with AKT and ErBb family 
members, where expression peaked slightly within the first 24 hours before slowly 
declining. However PTEN showed a 10 fold increase in magnitude post cisplatin 
exposure. 
 
97 
 
Cisplatin resistance can involve deregulation of the AKT/PTEN pathway separate from 
EGFR (270). Future work could look to intervene with RTK/AKT/PI3K signalling 
inhibitors to reverse resistant phenotypes with standard therapy or as targeted 
combinations, such as those used in Chapter 6 -  targeting EGFR and PI3K pathways.  
4.3.4 Conclusions and Future Prospects  
Toxicity effects of cisplatin can be severe for many patients. In such cases cisplatin 
dose regimens may need to be reduced or changed even if tumour sensitivity is seen. 
The ability to use a low dose cytotoxic to sensitize tumour cells to a second more 
tolerable anti-cancer agent is extremely desirable. Results for the sequential 
administration of cisplatin and EGFR inhibitors gefitinib and cetuximab are shown to be 
inconsistent and full explanations for sensitivity are, for the most part, still elusive.  
 
These data show the need for an array based approach to cellular adaptation and 
signalling studies, as cells have shown to utilize a variety of mechanisms to avoid drug 
induced stress and death. It was optimistic to think that these mechanisms could be so 
simply exploited to predict individual responses and be utilisable in effective 
sequential treatments. Other studies have compounding evidence for a multifaceted 
approach to drug resistance involving adaptation of mechanisms that are both drug- 
and tissue-dependent (271).  
 
The practical development of the sequential cellular and gene expression assay designs 
provided are evaluable tools which demonstrate the level of complexity of 
interconnecting pathways that work in harmony to either drive the cell into death or 
adapt for survival. It is however, unclear if the use of low dose cisplatin concentrations 
would reflect clinical outcomes where much higher doses are more commonly used. 
 
One way to move forward from this approach would be to use these techniques to 
look more closely at targets in and around known pathways that are utilised by 
neoplastic cells with the options for future pathway specific arrays.  
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Chapter 5 -  Cisplatin and RAS Effector Inhibition 
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5.1 Introduction 
Platinum compounds are DNA damaging agents, with cisplatin being one of the most 
widely used anti-cancer drugs. Cisplatin has long been augmented with other 
compounds to increase its efficacy. The intention here is to look at known molecular 
mechanisms to find novel approaches to cisplatin combinations. Signalling pathways 
have been shown to regulate cisplatin sensitivity. Therefore an ideal starting point 
would be combinations with specific agents targeting signalling pathways that 
contribute to cisplatin activity or resistance. This has already been shown with the 
VEGF inhibitor SU5416 which sensitizes ovarian cancer cells to cisplatin via suppression 
of nucleotide excision repair activity (272) or with the limited activity of the sequential 
administration of cisplatin and EGFR inhibitors gefitinib and cetuximab (Chapter 4 - ). 
 
Genotoxic stress like those produced by cisplatin can induce multiple signalling 
pathways. Of those the MAP kinase pathways including ERK are structurally related 
and run in parallel, with end points resulting in regulation of cell proliferation, 
differentiation and survival (273). Their involvements with receptors such as EGFR, 
HER2, IGFR and PDGFR along with RAS and RAF oncoprotein participation make it an 
ideal target for therapeutic intervention alongside cisplatin.  
 
Induction of ERK1/2 activity in response to cisplatin has been documented and is 
suggestive that ERK1/2 activation could provide cells with partial protection against 
the cytotoxic effects of cisplatin (274). Activation of ERK, induced by cisplatin exposure 
precedes p53-mediated DNA damage responses. ERK has the ability to directly 
phosphorylate p53 causing up-regulation of p21, GADD45, and MDM2 (53) thus, ERK 
activation may lead to cell cycle arrest allowing time for the repair of cisplatin-induced 
DNA damage via p53. Inhibition of ERK may therefore increase tumour cell sensitivity 
to cisplatin. 
 
A link between IGF1R signalling through the PI3K pathway and cisplatin resistance has 
been shown with ovarian cancer cell lines (275). Moreover the inactivation of 
downstream targets of the AKT/PI3K pathway has also been shown to sensitise ovarian 
cells to cisplatin (276, 277).  
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Treatment of other cisplatin resistant cells lines has shown a decrease of BCL2/BCLxL 
expression when treated with an mTOR inhibitor. Decreased levels of these anti-
apoptotic proteins can contribute to increased apoptosis within these cells (278). 
These resistant cells may also use alternative mechanisms such as the activation of the 
PI3/AKT survival pathway to oppose the insult from cisplatin. It is therefore logical to 
explore targets within these pathways to both enhance cisplatin sensitivity as well as 
reverse its resistance. 
 
Since many pathways downstream of RAS are controlled by multiple signalling 
cascades direct inhibition of RAS would not be sufficient to block them (62). Due to the 
overlapping of RAS signalling, increased signalling through one RAS effector pathway 
may occur at the expense of another.  
 
It is therefore logical to look at combinations based on downstream RAS effector 
pathways such as MEK/ERK, PI3K or mTOR as viable alternatives to direct RAS 
inhibition with the possibility of combining these with the standard cytotoxic cisplatin. 
5.2 Results 
Tumour material from 4 ovarian adenocarcinomas (1 chemo-naive and 3 with previous 
platinum/paclitaxel based treatment) was obtained and sensitivity tested against 
cisplatin alone and in combination with inhibitors of cisplatin related signalling 
pathways. These include active inhibitors of MEK1/2 (PD98059, LC Laboratories USA), 
PI3K (ZSTK474, LC Laboratories USA) and mTOR (sirolimus (rapamycin), LC Laboratories 
USA).  Where possible these data have been compared with real-time PCR gene 
expression profiles and relevant mutational analysis  
5.2.1 Single Agents 
Data shows some sensitivity to cells exposed to single agent sirolimus and ZSTK474 but 
not cisplatin and PD98059 over a range of concentrations thought to be clinically 
achievable. Taking an IndexSUM <300 as a threshold for sensitivity, all tumour-derived 
cell samples showed sensitivity to ZSTK474 while 50 % (2 of 4) of samples showed 
sensitivity when exposed to sirolimus. All samples showed resistance to PD98059 with 
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indexSUM ranging from 372-457. Cisplatin resistance was also seen in all ovarian 
samples tested (all IndexSUM >400) regardless of their prior exposure to cisplatin in vivo 
(1 chemo-naive, 3 post platinum + paclitaxel treatment) (Figure 42).    
5.2.2 Cisplatin Combinations  
Using the adapted 384 well ATP-HTCA assay, combinations of cisplatin with cisplatin 
related signalling targets could be analysed with dose escalating concentrations in a 
checkerboard style pattern; allowing analysis of dilutions of drug with static 
concentrations of another (8.3 Electronic Appendices: Checkerboard Design).  
 
Even though the MEK kinase inhibitor PD98059 showed minimal single agent activity 
not exceeding 50 % cellular inhibition (IndexSUM range 372-457) at low cisplatin 
concentrations, PD98059 could help dramatically increase the sensitivity in these 
ovarian tumours(Figure 36,Figure 37).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Sensitivity of ovarian tumour derived cells to cisplatin alone and with 
stepwise concentrations of the MEK inhibitor PD98059 
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This increase in sensitivity can be represented by a decrease in the mean IndexSUM 
from a resistant 410 (356-450) to a sensitive 195 (148-237). Results showed that by 
increasing the concentration of PD98059 this could augment cisplatin sensitivity 
independently of cisplatin dose escalation.  
Figure 37: Sensitivity of ovarian tumour derived cells to the MEK inhibitor PD98059 
alone and with stepwise concentrations of Cisplatin 
Ovarian cells showed a stepwise increase in sensitivity with the increase of static 
concentrations of the PI3K inhibitor ZSTK474 when combined with cisplatin (Figure 38). 
The combination of cisplatin and 2.16 µM ZSTK474 exceeded 90% tumour cell 
inhibition giving rise to a mean IndexSUM of 89 (35-131). This combinational effect was 
less pronounced when looking at static concentrations of cisplatin.  Activity of ZSTK474 
was shown to be greater with the addition of cisplatin at between 1.3-2.5 µM (Figure 
39).  
Addition of static doses of sirolimus (between 1.3-2 µM) to cisplatin concentrations 
increased ovarian tumour cell inhibition (Figure 40). The activity of this combination 
was shown to be effective mainly due to the activity of sirolimus. However, at higher 
sirolimus concentrations cisplatin could increase mean tumour cell inhibition from 61% 
to 87% (Figure 41).    
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Figure 38: Sensitivity of ovarian tumour derived cells to cisplatin alone and with 
stepwise concentrations of the PI3K inhibitor ZSTK474 
Figure 39: Sensitivity of ovarian tumour derived cells to the PI3K inhibitor ZSTK474 
alone and with stepwise concentrations of cisplatin 
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Figure 40: Sensitivity of ovarian tumour derived cells to cisplatin alone and with 
stepwise concentrations of the mTOR inhibitor sirolimus 
 
Figure 41: Sensitivity of ovarian tumour derived cells to the mTOR inhibitor sirolimus 
alone and with stepwise concentrations of cisplatin 
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5.2.3 Gene Expression and Mutation Status 
Tumours were tested for mutations in EGFR KRAS BRAF and PI3K (Table 13). Results 
showed them to be negative for all mutations tested suggesting that combinational 
sensitivity was due to the gene expression profile and not the mutations tested. 
 
Expression of multiple markers of DNA repair was observed in 3/4 tumour samples, 
with the sample taken from the chemo-naive patient (tumour 2) showing relatively 
increased levels (Figure 42). 
Figure 42: Sensitivity of ovarian tumour derived cells to cisplatin, PI3K inhibitor 
ZSTK474, mTOR inhibitor sirolimus and MEK inhibitor PD98059 alone and in 
combination (both with relative dose escalation), in relation to relative gene 
expression ratio data of signal transduction pathway targets (highlights show 
positive (green) and negative (pink) expression in relation to PBGD). 
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5.3 Discussion 
5.3.1 Single Agents 
Resistance to cisplatin was seen in all tumours tested regardless of prior treatment 
before tumour sample retrieval. This could result from a multitude of factors as 
tumours showed heterogeneous expression of efflux pump genes as well as increased 
expression of multiple targets of signalling pathways and apoptosis related genes. 
Cisplatin resistance has shown to be related to AKT/mTOR survival pathway, with 
resistant cells expressing a higher level of activated AKT (279).  
 
ZSTK474 was the most effective single agent tested with all tumours showing 
sensitivity with an Indexsum<300. PI3K has been shown to be a promising target for 
ovarian tumours, whether this is due to its possible disruption of AKT or other pathway 
targets. It is  important to consider that targeting downstream targets of AKT rather 
than AKT directly is more beneficial, as AKT also mediates certain biologically 
important cellular processes such as glucose metabolism which could give rise to more 
toxic side effects for patients  (280).  
 
The mTOR inhibitor sirolimus showed some sensitivity in these cisplatin resistant cells. 
Sensitivity of mTOR inhibitors including sirolimus can be limited in some tumours due 
to the presence of negative feedback loops, where AKT and ERK become 
phosphorylated through mTORC1 and mTORC2 (281).  Sirolimus has shown to only 
partially block translation by efficiently inhibiting S6 kinase 1 (S6K1) but not eIF4E. Due 
to the inhibition of S6K1-dependent feedback loops rapamycin also indirectly 
upregulates PI3K activity promoting cell survival  (282). 
5.3.2 Combinations 
Resistance was seen in all tumours to the MEK inhibitor PD98059. Its combination with 
cisplatin showed little increase in activity suggesting there was little evidence for a role 
of the RAS/RAF/MEK/ERK pathway in these tumours. However, at low cisplatin 
concentrations PD98059 was shown to increase sensitivity more noticeably.  
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This study showed an increase in sensitivity to sirolimus and cisplatin combinations 
when compared with either single agent in ovarian tumours. Inhibition of mTOR has 
been shown to restore activity of cisplatin in lung cancer (278, 283). Sirolimus 
inhibition has been shown to activate AKT/ERK via feedback mechanisms. This suggests 
a role of the MEK/ERK pathway in enhancing cisplatin induced apoptosis (284, 285), 
with prolonged ERK activation promoting cell death (284).  
 
This study has shown that augmenting cisplatin with the PI3K inhibitor ZSTK474 may be 
an effective strategy for ovarian cancer. It has already been shown that inhibition of 
PI3K activity decreases the survival of the cells exposed to Cisplatin (248, 286). As AKT 
activation has been shown to occur in many cisplatin resistant tumours, the addition of 
PI3K inhibitors to first line cisplatin treatment may result in a more prolonged response 
with the option of reducing cisplatin concentrations (286). 
5.3.3 Checkerboard Dose Escalation 
Using the checkerboard design to evaluate dose escalation studies with these 
combinations proved invaluable as simple combination analysis would not have shown 
the extent of sensitivity seen with these agents at different static dose escalations.  
 
Combining molecular targeted agents with cisplatin in some instances has shown that 
it may be possible to use lower doses of cisplatin (than those currently employed 
clinically) to achieve similar or greater cellular inhibition than those seen with single 
agent cisplatin. Although PD98059 never reached clinical evaluation, combinations of 
this type of inhibitor along with cisplatin could be beneficial. Combinations could give 
rise to a reduction in side effects such as nephrotoxicity associated with cisplatin 
toxicity without reducing the cytotoxic activity within patients who are unable to 
tolerate higher dose cisplatin regimens. 
5.3.4 Gene Expression 
Previous studies comparing TaqMan array and ATP-TCA drug sensitivity in ovarian 
cancer had shown correlation of 10 genes with cisplatin sensitivity (Rad51, IGF1R, p53, 
Topo I, MRP5, survivin, HSP60, BCRP, Mcl-1 and Ki67 in order of greatest contribution) 
(209). With such small numbers here statistical correlation was not performed. 
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However, expression of genes could be observed within known mechanisms of 
chemoresistance, membrane drug pumps and DNA repair (see Electronic Appendices: 
8.3; GER RAS effector Inhibitors, for full data).  
 
Cisplatin resistance was seen in all tumours tested however; those with greatest 
resistance showed to have reduced levels of over 5 DNA-repair mechanisms.  A trend 
in sirolimus sensitivity could be seen with EGFR, HER2 and HER3 expression suggesting 
the potential rationale for combinations of this mTOR inhibitor with a RTK inhibitor. 
 
Greatest resistance was seen for the MEK inhibitor PD98059 however, there were no 
target genes directed for the RAS arm of RTK pathway to associate this with. Greater 
sensitivity was seen with ZSTK474 and sirolimus single agents and combination with 
cisplatin. Gene expression data for theses tumours showed greater expression of 
multiple targets within the PI3K/AKT/mTOR pathway. This may suggest that the 
PI3K/AKT/mTOR pathway is more prominent than the RAS/RAF/MEK/ERK pathway in 
ovarian tumours. 
5.3.5 Conclusion 
Although platinum agents are still one of the most widely used cytotoxic agents in 
ovarian cancer, resistance and toxicity are still major problems. While this study 
included small numbers of tumour samples, evidence of greater sensitivity could be 
seen with combinations of cisplatin and inhibitors of targets downstream of RAS.  
Evidence for the reduced cisplatin concentration used in these combinations may 
provide a rationale for patients who develop severe platinum based toxicity. 
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Chapter 6 -  Targeting EGFR and PI3K Pathways 
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6.1 Introduction 
EGFR is found to be expressed in ovarian cancer (287). Anti-EGFR antibodies and small 
molecule inhibitors have been used in ovarian cancer patients with little or no success 
in terms of clinical response (250, 288).  This is consistent with previous data on TKIs 
activity in ovarian cancer primary cell cultures where only occasional evidence of 
gefitinib activity was observed and not at a level likely to produce clinical response 
(104).  While data from non-small cell lung cancer (NSCLC) would suggest that this may 
be due to a lack of activating mutations, it has also been suggested that an anti-EGFR 
strategy may also fail due to the presence of alternate activated pathways (287, 289).  
Inhibition of a solitary signal transduction pathway is often inefficient due to activation 
of alternative signalling cascades or receptor switching (261, 290-292).  The 
PI3K/AKT/mTOR pathway is of importance in ovarian cancer (293) and is activated by a 
number of known molecular defects, particularly PIK3CA mutation or amplification in 
up to 30% and PTEN loss in up to 40% of patients (294, 295).  In addition, the insulin 
like growth factor (IGF) pathway, as well as other human epidermal growth factor 
receptor (HER) pathways are present and thought to be active in ovarian cancer (296, 
297).   
 
Given the observation of limited activity of gefitinib and the potential for combination 
with inhibitors of the PI3K/AKT/mTOR pathway, It was decided that the best course of 
action would be to examine the possibility that EGFR targeted agents would be more 
effective against ovarian cancer in combination with other inhibitors specific to the 
RTK/AKT/PI3K/mTOR pathway (Figure 43).  Di Nicolantonio and colleagues developed a 
panel of isogenic human cell lines by employing homologous recombination (by knock-
in ) to characterize the response of the specific mTOR inhibitor everolimus to those 
cells containing specific mutations (298). Using paired cell lines (isogenic and parental); 
drug sensitivity versus resistance was accurately assessed, with any phenotypic 
changes being a direct result of the introduced mutations. The DNA-modiﬁcations 
made to these commercially available cell lines are made within the endogenous gene 
so as to closely recapitulate the genetic events leading to the desired disease of study.  
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Figure 43: Growth factor receptor tyrosine kinase pathway signalling including points 
at which gefitinib, erlotinib, ZSTK474 and sirolimus interact 
 
This comparative technique was also employed here. Isogenic cell lines for ovarian 
cancer were not available, so instead the nearest alternative were chosen. These were 
the human non-tumorigenic immortalized breast epithelial cells MCF10a containing 
known activating mutations in EGFR, BRAF, AKT and PI3K along with the parental line 
which is wild type for these mutations.  These were tested for sensitivity against 
EGFR/AKT/PI3K/mTOR pathway inhibitors gefitinib (Iressa), erlotinib (Tarceva), 
sirolimus (Rapamycin) and ZSTK474, a pan-PI3K inhibitor (299).  These combinations 
were then tested against primary cell cultures from human ovarian tumours to 
determine whether this strategy might have potential for clinical application. 
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6.2 Results 
In both isogenic cell lines and tumour-derived cells, the ATP-TCA was used to 
determine the effect of EGFR inhibitors (gefitinib and erlotinib) alone and in 
combination with inhibitors of the AKT/PI3K/mTOR pathway.  In the primary cell 
cultures these data have been compared with RT-PCR gene expression profiles and 
relevant mutation analysis to determine mechanisms of sensitivity and resistance.  
 
6.2.1 Effect of Single Agents on Isogenic MCF10a Cell Lines 
The parental MCF10a cell line showed greater resistance to gefitinib than those with 
mutations in EGFR, PI3K, BRAF or AKT (Figure 44). Greatest sensitivity was seen within 
the PI3K mutated cells where IndexSUM values decreased from a relatively resistant 423 
to considerably more active 120 and 64 for the H1407R and E545K mutations of 
PI3KCA respectively.   MCF10a cells were more sensitive to erlotinib (IndexSUM = 188) 
than gefitinib (IndexSUM = 423).  The reasons for this are unclear.  Changes in sensitivity 
caused by the mutations were less pronounced in response to erlotinib exposure.  The 
PIK3CA mutation E545K still became the most sensitive phenotype, but the effect of an 
AKT mutation produced a slightly more resistant phenotype (IndexSUM = 227) when 
compared with the parental line (IndexSUM = 188). However, both showed sufficient 
cellular inhibition to be classed as active agents in this setting with an indexSUM <300 
(104).  
 
All mutated MCF10a cell lines showed sensitivity to the PI3K inhibitor ZSTK474 
(IndexSUM<300) with EGFR and AKT mutations having no effect on the activity of this 
agent. Results with these mutations were similar to the parental line.  PI3K mutations 
conferred greater sensitivity to ZSTK474 compared with the parental line, while cells 
containing the BRAF mutation V600E showed a slightly more resistant phenotype.  
 
Sirolimus was the least active of the four inhibitors tested (Figure 44). Only MCF10a 
cells harbouring EGFR and PIK3CA (E545K) mutations showed sensitivity with IndexSUM 
272 and 254 respectively which was an increase compared with the parental line 
IndexSUM 333.  Cells containing the BRAF mutation (V600E) again showed the most 
resistant phenotype with an IndexSUM 533. 
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6.2.2 Effect of Combinations on Isogenic MCF10a Cell Lines 
Combination of the EGFR inhibitors with either ZSTK474 or sirolimus resulted in greatly 
increased cellular inhibition (Figure 44), with sensitivity IndexSUM values in all MCF10a 
cell lines falling below 200. The effects of mutations on sensitivity were still observable 
with cells containing BRAF mutations, though these showed less sensitivity to 
combinations when compared with the parental line.  MCF10a cells containing the 
PI3K mutation H1047R showed little sensitivity to single agent sirolimus. In 
combination with EGFR inhibitors these cells were still seen to be more resistant than 
their parental counterparts and more resistant than MCF10a cells containing the 
PIK3CA E545K mutation. Interestingly, MCF10a cells containing PI3K mutations (E545K 
and H1047R) showed greater sensitivity to EGFR inhibitor gefitinib than the cells 
containing the EGFR mutation (∆ E746-A750). 
 
Activity at higher concentrations in all combinations was mainly due to synergy (100% 
with EGFR and PI3K inhibitors 83% (5 of 6) for EGFR and mTOR inhibitors). This is 
reflected by the combination indices calculated by the Chou and Talalay method on 
the median dose-response curve (Table 11) (225).  Antagonism was seen more 
predominately for drug combinations at lower concentrations where only 17% (1 of 6) 
of cells showed any synergy.  
 
Table 11: Effect of combining EGFR inhibitors with PI3K and mTOR inhibitors on 
MCF10a cell lines using Chou and Talalay combination index calculated for 50% cell 
death (CI50) and for 90% cell death (CI90), where synergy is <0.8, additivity is 
between 0.8 and 1.2 and antagonism is >1.2 
 
<0.8 0.8-1.2 >1.2 <0.8 0.8-1.2 >1.2
Gefitinib + ZSTK474 6 0 0 3 2 1
Erlotinib + ZSTK474 6 0 0 2 3 1
Gefitinib + Sirolimus 5 1 0 4 1 1
Erlotinib + Sirolimus 5 0 1 2 3 1
Combination Index (n) CI90 Combination Index (n) CI50
Drug Combination
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Figure 44: Sensitivity of gefitinib, erlotinib, ZSTK474 and sirolimus alone and in combination on the parental MCF10a cell line compared to 
isogenic clones with EGFR, BRAF, AKT and PI3K mutations 
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6.2.3 Effects of Single Agents on Tumour Derived Cells 
Heterogeneity between ovarian tumours was observed for all four targeted agents. 
The majority of ovarian tumours tested were found to be resistant to EGFR inhibitors 
with only 2 /10 for gefitinib and 1/10 for erlotinib respectively (1 in 10), showing strong 
single agent activity with an Index SUM<300 (Figure 45). Greater sensitivity was seen 
with the PI3K inhibitor ZSTK474 with 4/10 tumours showing single agent sensitivity 
(Figure 45). Inhibitors of mTOR (sirolimus) have been shown to elicit a predominately 
cytostatic response (300) and so not surprising only 1/10 tumours showed any 
sensitivity in this type of assay where cell death is the end point (Figure 45). 
 
Figure 45: Mean sensitivity of ovarian tumour cells to the EGFR, mTOR and PI3K 
inhibitors alone and in combination (error bars indicating range) 
6.2.4 Effect of Combinations on Tumour Derived Cells 
In the ovarian tumour samples the combinations of EGFR inhibitors with PI3K and 
sirolimus inhibitors showed greater sensitivity compared with their corresponding 
single agent activity (Figure 45).  
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Some of the activity observed with gefitinib and ZSTK474 was due to both synergism 
and additivity at lower concentrations (50% and 20% respectively), while 50% of 
tumours also showed additivity at higher doses. This is reflected by the combination 
indices calculated by the Chou and Talalay method on the median dose-response curve 
(Table 12) (225).  Antagonism was seen more predominately for this combination at 
higher concentrations where 50% of samples had >1.2 combination index for 90% 
inhibition.  
Table 12: Effect of combining EGFR inhibitors with PI3K and mTOR inhibitors for 
ovarian tumours using Chou and Talalay combination index calculated for 50% cell 
death (CI50) and for 90% cell death (CI90), where synergy is <0.8, additivity is 
between 0.8 and 1.2 and antagonism is >1.2 
 
The combination of erlotinib and ZSTK474 showed similar effects to that of the 
gefitinib and ZSTK474 combination (example of individual tumour sensitivity (Figure 
46). A pronounced increase in sensitivity could be seen with co-administration of these 
agents. Results showed synergy at lower concentrations while antagonism was seen at 
90% inhibition, where 70% of samples had >1.2 combination index (Table 12).  
 
The combination of sirolimus and EGFR inhibitors though not as effective as the EGFR 
and PI3K combinations showed some increase in sensitivity to its combination 
compared to individual single agent activity (example of individual tumour sensitivity 
Figure 47). Although some synergy was observed the sensitivity increase seen with this 
combination was predominantly due to an additive effect (Table 12). An inverse 
relationship could be seen in the single agents activity of both EGFR inhibitors and 
sirolimus, whereby sensitivity to one referred resistance to the other (Figure 48 and 
Figure 49).  
<0.8 0.8-1.2 >1.2 <0.8 0.8-1.2 >1.2
0 5 5 5 2 3
0 3 7 5 3 2
0 4 6 2 3 4
0 5 5 4 3 2
Drug Combination
Combination Index (n) CI90 Combination Index (n) CI50
Gefitinib + ZSTK474
Erlotinib + ZSTK474
Gefitinib + Sirolimus
Erlotinib + Sirolimus
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Figure 46: Example of sensitivity of an ovarian tumour to EGFR and PI3K inhibitors 
alone and in combination  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47: Example of sensitivity of an ovarian tumour to EGFR and mTOR inhibitors 
alone and in combination 
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Figure 48: Comparison of sensitivity of ovarian tumours to gefitinib versus that of 
sirolimus 
 
 
 
 
 
 
 
 
 
Figure 49: Comparison of sensitivity of ovarian tumours to erlotinib versus that of 
sirolimus 
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(c.1799T>A - V600E), PI3K (c.3140A>G - H1047R and c.1633G>A - E545K) and AKT 
(c.49G>A - E17K). All cell line mutations were confirmed where ARMS kits for the 
relevant mutation were available (Qiagen Ltd, Manchester). Confirmation of mutations 
R² = 0.5178
0
100
200
300
400
500
600
0 100 200 300 400 500 600
S
ir
o
li
m
u
s 
(I
n
d
e
x
SU
M
)
Gefitinib (IndexSUM)
Sensitivity of Gefitinib Vs Sensitivity of 
Sirolimus in Ovarian cancer cells (n=9)
R² = 0.6563
0
100
200
300
400
500
600
0 100 200 300 400 500 600
S
ir
o
li
m
u
s 
(I
n
d
e
x
SU
M
)
Erlotinib (IndexSUM)
Sensitivity of Erlotinib Vs Sensitivity of  
Sirolimus in Ovarian cancer cells (n=9)
 119 
 
were obtained for all but AKT in this way. The parental MCF10a cell line was also 
screened against all available mutation tests to confirm mutation exclusion.   
 
Tumours were tested for common mutations with EGFR, KRAS, BRAF and PI3K genes 
(Table 13). All tumours tested negative for the common mutations of EGFR, PI3K and 
BRAF. A single serous adenocarcinoma was shown to have a KRAS c.35G>T (G12V) 
mutation. The G12V mutation results in an amino acid substitution at position 12 in 
KRAS, from a glycine (G) to a valine (V).  This tumour showed decreased sensitivity to 
all EGFR, PI3K and mTOR inhibitors tested alone and in combination, with IndexSUM 
values indicative of resistance (504 gefitinib, 455 erlotinib, 347 ZSTK474 and 396 
sirolimus. Combination IndexSUM values for gefitinib + ZSTK474 303, Erlotinib + ZSTK474 
303, gefitinib + sirolimus 401 and erlotinib + sirolimus 336). Interestingly gefitinib 
showed greater single agent resistance than erlotinib.   
Table 13: Activating mutations tested within EGFR, KRAS, PI3K and BRAF genes  
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6.2.6 Gene Expression and Sensitivity 
Relative gene expression data for ovarian tumours showed varying expression levels of 
multiple growth factor receptors including EGFR, HER2, HER3, IGF1R and IGF2R (Figure 
50 and Figure 51) many of which showed some linear dependence with EGFR, PI3K and 
mTOR inhibitor sensitivity (p<0.05) (Table 14). EGFR inhibitors showed contrasting 
correlating gene expression data compared with PI3K and mTOR inhibitors where 
positive correlation of target genes seen in EGFR inhibitors was seen to be negatively 
correlated in ZSTK474 and sirolimus (Table 14). 
 
Table 14: Correlation of relative gene expression with drug sensitivity using paired 
Pearson’s correlation. 
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Figure 50: Waterfall plots reflecting sensitivity of ovarian tumours to RTK pathway inhibitors and their relation to relevant gene expression targets 
(highlighted cells indicate relative gene expression where target Ct value is more than double (green)/half (pink) that of PBGD). 
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Figure 51:  Waterfall plots reflecting sensitivity of ovarian tumours to combinations of RTK pathway inhibitors and their relation to relevant gene 
expression targets (highlighted cells indicate relative gene expression where target Ct value is more than double (green)/half (pink) that of PBGD). 
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6.3 Discussion 
Combinations of EGFR and PI3K inhibition show synergistic activity against ovarian 
cancer, despite the absence of EGFR mutations examined in this tumour type. There is 
heterogeneity of activity of the different drugs and combinations with different 
mutations in the MCF10a cell line.  Similar heterogeneity is seen in clinical trials with 
single agents in ovarian cancers and it will be important to define the pathways to 
future stratify patients for optimal treatment schedules.  The gene expression data 
indicate that this is feasible but suggests that determinants of resistance may not be 
limited to the target pathways, but also involve both the apoptotic potential of the cell 
and classical drug resistance mechanisms relating to drug efflux pumps. 
 
In MCF10a cell lines, PI3K mutations lead to higher activity of EGFR inhibitors and PI3K 
inhibitors, while AKT mutation E17K leads to excessive growth with the mTOR inhibitor 
sirolimus. Limitations of sirolimus activity in the E17K mutated line could be due to the 
amalgamation of multiple factors. These could include the continued PI3K and AKT 
activation via feedback loops caused by mTOR inhibition with sirolimus, as well as 
activation of AKT1 by means of pathological localisation to the plasma membrane 
stimulating downstream signalling caused by the E17K mutation (301-303).  
 
Mutations in PI3K (H1047R) have been shown to enhance HER2-mediated 
transformation by amplifying the ligand-induced signaling output of the ErbB family of 
RTK’s (304). It could be assumed that because PI3K mutations drive ErbB related 
receptor addiction in these cells it would make them more susceptible to RTK 
inhibition (like those seen here with gefitinib). 
 
EGFR/PI3K and EGFR/mTOR combinations were all more active than their single 
agents, especially when PI3K mutations were present. However, it was found that 
E545K cells were more sensitive than H1047R suggesting that not all PI3K mutations 
will result in the same activity in combination.   
 
The number of ovarian tumours studied was too small to determine whether this is an 
issue in practice as PIK3CA mutations are rare in ovarian cancer. The reality that not all 
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activating mutations within a given gene are comparable may also be important in 
other tumour types and recapitulates data from Di Nicolantonio et al suggesting that 
not all KRAS mutations in colorectal cancer are equally effective in conferring 
resistance to anti-EGFR antibodies (298).  
 
This study identified varied inhibition of ovarian tumours when exposed to EGFR, PI3K 
and mTOR inhibitors. The greatest single agent activity was observed with the PI3K 
inhibitor ZSTK474 confirming the importance of PI3K signalling within these tumours. 
Evidence for the deregulation of PI3K/AKT signalling in ovarian cancer includes gain of 
function mutations, amplifications of PI3K and AKT genes as well as allelic imbalance 
and mutations in PTEN (305).  
 
All drug combinations showed greater activity than their single agent counterparts, 
with ZSTK474 and EGFR inhibitor combinations showing greatest activity. Antagonism 
with these combinations was seen at higher concentrations suggesting that there may 
be a biologically optimum dose beyond which activity is lost. The strategy to hit 
multiple aspects to signalling pathways thought to be key to ovarian cancer control of 
growth and survival proved to be more effective than single agent administration in all 
of the tumours studied. With inhibition of EGFR via tyrosine kinase inhibitors, 
continued expression of HER2, HER3, IGFR and c-MET goes unchecked. Subsequent 
heterodimerisation of these unchecked receptors has been shown to increase 
downstream signalling via the PI3K-AKT pathway resulting in resistance to tyrosine 
kinase inhibitors gefitinib and erlotinib (306). Therefore, the addition of further agents 
targeting such PI3K compensatory pathways or multi-targeted HER inhibitors (e.g. 
lapatinib) might result in greater effects. Such a strategy is feasible but, would of 
course require phase I trials with careful monitoring of toxicity. 
 
Expression of genes involved in growth factor receptors and substrates, apoptosis and 
drug transport were seen to correlate well with the activity of single agent EGFR 
inhibitors in ovarian tumours. In these agents increased levels of EGFR, HER2 or HER3 
conferred sensitivity to these inhibitors, while increased IGF2R expression inferred 
greater resistance (Figure 50).  The inverse to this relationship could be seen with 
ZSTK474 and sirolimus sensitivity. The inverse relationship between the effects of gene 
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expression for these receptors may give rise to some of the antagonism seen with the 
combination of these inhibitors and is explicable in terms of the pathway (Figure 43).   
 
In the presence of the EGFR inhibitor gefitinib, PI3K signalling can be maintained by an 
activated IGF1R pathway (74, 119). Therefore it could be suggested that for effective 
single agent anti-EGFR therapy to be effective in EGFR wild type ovarian tumours it 
would require cells to have active EGFR dominant ErbB signalling in the absence of 
IGFR signalling pathways. In anti-EGFR resistant tumours showing this profile, further 
alternate signalling mechanisms may be employed including continued signalling via 
MET by driving ErbB3 dependent activation of PI3K. 
 
Cellular Inhibition with PI3K inhibitor ZSTK474 was shown to be more effective in 
tumours with low receptor tyrosine kinase (RTK) gene expression.  It has been shown 
that inhibition of PI3K can result in feedback upregulation of expression and 
phosphorylation of multiple RTK’s in breast cancer (307).  The identification of these 
feedback mechanisms emphasise the need for a multiple approach to treatment, by 
combining RTK and PI3K inhibitors as shown here some of this effect may be muted. 
 
This study shows the possible importance of two drug transporters in the sensitivity of 
erlotinib, ZSTK474 and sirolimus in ovarian cancer. Both gefitinib and erlotinib 
previously have shown direct inhibition of drug efflux function of MDR1/ABCB1 and 
BCRP/ABCG2. Their expression has been found to be elevated in cells with acquired 
gefitinib resistance (252, 308). The expression of ATP Binding Cassette (ABC) 
transporters MRP1/ABCC1 and TAP4/ABCB4 had a negative effect on drug sensitivity 
to the EGFR inhibitor erlotinib, whereby drug resistance increased along with the level 
of gene expression. However, the reverse was true for the sensitivity to ZSTK474 and 
sirolimus where an increase in transporter expression meant an increase in sensitivity.  
 
Some limitations were imposed on this study by our use of cells from ascites. This 
limited our ability to perform immunohistochemistry as most cells obtained were used 
in the primary cell culture experiments and no corresponding histological material was 
obtained. However, primary tumour material is still probably more relevant than cell 
lines from long term culture with hyperactivated growth pathways. Unfortunately, the 
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sample size for this study meant that there were very few tumours with activating 
mutations within relevant targets. Breast epithelial isogenic cell line MCF10a data 
showed very similar results to ovarian tumours in relation to drug sensitivity and 
showed the importance for molecular characterisation of tumours, where possible 
including gene expression as well as mutation analysis. 
 
In conclusion, this study shows very encouraging activity of a combination of EGFR and 
PI3K inhibitors: combined HER inhibitors such as lapatinib may also be interesting 
though they were not tested here. Further work should include PTEN and AKT 
mutation analysis as well as PIK3CA amplification (possible via fluorescent in situ 
hybridisation). Possible Phase I/II clinical trials with these agents should include 
pharmacodynamic endpoints and molecular characterisation to identify patients most 
likely to benefit from this strategy. 
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Chapter 7 -  Targeting the Mevalonate Pathway 
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7.1 Introduction 
The mevalonate pathway provides cells with isoprenoids which are fundamental for 
cell growth and survival. Inhibition of targets involved in this pathway has shown 
promising results for the treatment of some cancers (149, 309). Two such agents 
fluvastatin and zoledronic acid have shown activity at points distant to each other 
along this pathway and have shown to be directly effective in tumour cell inhibition 
(Figure 4, page 23) (147, 310). The rationale behind using these two inhibitors within a 
single pathway stems from the idea that you could amplify the single pathway 
blockade limiting cross reactivity by targeting points at distant sites.  
 
Statins such as fluvastatin are potent competitive inhibitors of 3-hydroxy-3-
methylglutaryl- coenzyme A (HMG-CoA) reductase, and are widely used to treat 
patients with high cholesterol and coronary heart disease (311). Although still 
controversial, statin use in patients diagnosed with ovarian cancer has shown to be 
associated with improved survival (312, 313). 
 
The newer N-bisphosphonates such as zoledronic acid (Novartis) are inhibitors of 
farnesyl pyrophosphate synthase (FPPs), reducing the amount of both FPP and GGPP 
available for Ras prenylation (310, 314). In addition to the loss of prenylated proteins, 
zoledronic acid  causes intracellular accumulation of isopentenyl pyrophosphate (IPP) 
which consequently induces the biosynthesis of the pro-apoptotic ATP analog ApppI 
(1-adenosin-5′-yl ester 3-(3-methylbut-3-enyl) ester triphosphoric acid) (150, 152, 153). 
ApppI has the subsequent ability to directly induce apoptosis through the blockade of 
mitochondrial adenine nucleotide translocase (152). 
 
Studies have shown direct activity of the N-bisphosphonate zoledronic acid in an ATP-
based tumour chemosensitivity assay (ATP-TCA) against breast and ovarian tumours 
(147, 310). Studies here show the continuation of the ATP-TCA mevalonate studies 
carried out by Knight et al. examining effects of fluvastatin sequentially and in 
combination with zoledronic acid against primary ovarian cancer cells in vitro.  
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7.2 Results 
A total of 11 ovarian tumours were tested for sensitivity to zoledronic acid and 
fluvastatin, alone and in combination. Alongside these, 8 ovarian tumours were tested 
for sequential administration of these agents. Zoledronic acid (hydrated sodium salt) 
was obtained from Novartis (Basel, Switzerland) and fluvastatin (344095-25) was 
obtained from VWR International (Leicestershire, UK). Both drugs were diluted in 
complete assay media (CAM) to concentrations previously thought to be clinically 
achievable (Zoledronic acid 2.2 – 69 μM and fluvastatin 0.7 – 24 μM). Combinations of 
zoledronic acid and fluvastatin were tested by simultaneous addition as per the 
method outlined in the methods chapter (2.2 ATP-TCA). 
7.2.1 Effects of Single Agents 
There was considerable heterogeneity between individual tumours in their response to 
zoledronic acid and fluvastatin (Figure 52- Figure 54). Data shows sensitivity to cells 
exposed to both single agents at clinically achievable concentrations. Taking an 
IndexSUM <300 as a threshold for sensitivity, all tumour-derived cell samples showed 
sensitivity to zoledronic acid while 82% (9 of 11) of samples showed sensitivity when 
exposed to fluvastatin.  
7.2.2 Effects of Combination 
Sensitivity was seen in all ovarian tumours to the zoledronic acid and fluvastatin 
combination with less heterogeneity at higher concentrations compared with their 
single agent counterparts (Figure 54). This combinational sensitivity shows greater 
activity compared with either single agent (Figure 55). Using combinational indices 
(225) data shows synergistic effects for zoledronic acid and fluvastatin combinations in 
82% (9 of 11) of samples (Table 15) where values were <0.80. The median CI50 and 
CI90 values were 0.67 (0.131-1.29) and 0.37 (0.11-1.85) respectively both showing 
synergy. Only 1 sample showed any additivity and antagonism for CI50 and CI90.  
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Figure 52: Heterogeneity of ovarian tumour derived cells to zoledronic acid 
 
 
Figure 53: Heterogeneity of ovarian tumour derived cells to fluvastatin 
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Figure 54: Heterogeneity of ovarian tumour derived cells to the combination of 
zoledronic acid and fluvastatin 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: Chemosensitivity of tumour derived cells to zoledronic acid and fluvastatin 
alone and in combination. 
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Table 15: combinational indices showing the synergistic effects of zoledronic acid and 
fluvastatin on the number of ovarian samples (225) 
 
 
 
 
7.2.3 Sequential Effects 
Sequential drug experiments show that ovarian tumour cells exposed to fluvastatin 
exhibit little or no differences in their sensitivity to fluvastatin regardless of whether 
they have been pre-exposed to zoledronic acid (Figure 56). Greater changes in 
zoledronic acid sensitivity were observed when fluvastatin was given as a 24 hour pre-
treatment, 71% (5 of 7) of samples showed an increase in zoledronic acid resistance 
when pre-exposed to fluvastatin compared with 29% (2 of7) which showed an increase 
in zoledronic acid sensitivity (Figure 57). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: Effect of sequential zoledronic acid and fluvastatin on ovarian tumour 
derived cells 
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Figure 57: Effect of sequential fluvastatin and zoledronic acid on ovarian tumour 
derived cells 
7.2.4 Substrate Replacement 
Substrate replacement experiments were conducted with a single tumour derived 
ovarian cancer from which large numbers of cells were obtained. Substrates included 
farnesyl diphosphate (FPP) (Echelon Biosciences Inc, US, cat: I-0150), mevalonate 
(Sigma, UK cat: M4667), farnesol (Sigma, UK, cat: F203), and Geranylgeraniol (GGOH) 
(Sigma, UK cat: G3278) these were tested via simultaneous addition or pre-incubation 
using a static concentration. 
 
No evidence of toxicity was seen when cells were exposed to farnesol, GGOH, 
mevalonate and FPP alone (Figure 58). Replacement and pre-incubation experiments 
were performed in various combinations with zoledronic acid and fluvastatin showing 
that in certain incidences the pathway blockade could be reversed (Figure 59- Figure 
61).  
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FPP addition only weakly reversed the effects of fluvastatin; the combination of 
zoledronic acid and fluvastatin and combination of zoledronic acid, fluvastatin and 
mevalonate (5 µM) (Figure 59). 
 
Addition of farnesol and GGOH to zoledronic acid and zoledronic acid and fluvastatin 
showed no effects sequentially or in combination (Figure 60 and Figure 59).  
 
A reversal of fluvastatin activity was shown in the presence of increasing mevalonate 
concentration from an IndexSUM of 185 for single agent fluvastatin to 499 with 
1537µM of mevalonate. Mevalonate had little effect of downstream inhibition of the 
zoledronic acid pathway alone or in combination with fluvastatin (Figure 62). 
 
Figure 58: Sensitivity of an ovarian tumour to mevalonate pathway substrates as well 
as zoledronic acid and fluvastatin alone and in combination  
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Figure 59: Sensitivity of an ovarian tumour sample to zoledronic acid alone and in 
combination with fluvastatin and mevalonate with FPP substrate replacement 
Figure 60: Sensitivity of an ovarian tumour to zoledronic acid alone and in 
combination with fluvastatin and GGOH substrate replacement (-> indicating 
sequential administration + indication combination administration) 
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7.3 Discussion  
It has been suggested that the underlying mechanism for the activity of zoledronic acid 
and fluvastatin involves Ras prenylation (147). Their use in combination has shown to 
produce enhanced effects compared to single agent activity in ovarian cancer (Figure 
55).  
 
Observations of a marked reduction in sensitivity seen in some tumours when 
zoledronic acid follows fluvastatin sequentially are in contrast to what would be 
expected. When given before the bisphosphonate statins should, theoretically, be able 
to significantly reduce the entry of mevalonate into the pathway, allowing zoledronic 
acid to further block any remnants of downstream substrates resulting in increased 
efficacy of the combination. Sequential data suggests that in some samples zoledronic 
acid is far less effective when given after fluvastatin. Short exposure to fluvastatin may 
be enough to alter pathway dynamics rendering zoledronic acid less effective or, this 
effect may be a result of alternative mechanisms in play, such as an altered function of 
Ras specific to these samples. 
 
Suggestions have been made for a metabolite of ATP known as ApppI (Figure 4, Page 
23) to be responsible for some of the toxic effects of N-bisphosphonates (151, 152, 
154, 155). Sequential treatment in which zoledronic acid is given prior to fluvastatin 
shows no real increase in sensitivity compared with single agent fluvastatin. The main 
synergistic qualities from zoledronic acid in this combination may therefore come from 
the accumulation of ApppI over time where exposure exceeds 24 hours. 
 
The pharmacologic effects of fluvastatin are greatly reversed by treatment with 
mevalonate, suggesting that the downstream inhibition of geranylgeranylation and 
farnesylation of cellular proteins plays a critical role in its anticancer effect. This effect 
is less substantial when zoledronic acid is added to this combination. Zoledronic acid 
activity was not comparably reversed by FPP, while no effect was seen with GGOH or 
the farnesylated protein farnesol, suggestive of an effect more consistent with the 
alternative ApppI mechanism. 
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The direct anti-cancer synergistic results obtained from the combination of zoledronic 
acid and fluvastatin in ovarian tumour derived cells puts forth a rationale that it may 
be useful for treatment of ovarian cancer. 
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Chapter 8 -  Discussion and Future Work 
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The purpose of this study was the development and adaptation of techniques to 
investigate neoplastic molecular pathways and how they react when exposed to 
standard and targeted chemotherapy. With the growing difficulty to obtain viable 
fresh tissue in the quantities required for these studies it was necessary to look closer 
at the tumour types which would generate sufficient cellular material. This came 
mainly in the form of ascitic fluid from ovarian cancer patients. Ascites is the 
accumulation of fluid in the peritoneal cavity and in ovarian cancer this can be rich in 
cellular material. Many patients with ovarian ascites will undergo palliative 
paracentesis, the contents of which are routinely discarded. Obtaining this material 
has been valuable to these studies. 
 
Ovarian cancer is the second most common gynaecological cancer in the UK. Its high 
mortality is in part due to the difficulty of making an early diagnosis as ovarian cancer 
often develops without well-defined symptoms. This leads to a large majority of 
patients presenting with advanced cancer (stage III) at diagnosis (315). First line 
treatment for this disease is usually aggressive and can include a combination of 
surgery, chemotherapy or radiotherapy. Relapse can often occur within 6 months with 
residual tumour becoming highly resistant.  
 
There are many mechanisms by which cells resist drugs. Often exposure to one drug 
results in the acquisition of resistance to a broad range of chemically unrelated 
compounds (multidrug resistance). These studies have further confirmed that this 
adaptation process can begin to occur in a matter of hours, with up/down regulation 
of target genes involved in proliferation, DNA repair, apoptosis, cellular detoxification 
and drug pumps (78).  
8.1.1 Targeting Cells through Adaptation 
The idea of molecular chess and specific predictive oncology using designer sequential 
therapy is unlikely to come to fruition at present. It may be very difficult to predict the 
precise cellular adaptation paths a specific tumour will take when given that a single 
clonal tumour cell line taken from the same passage on the same day and exposed to 
the same drugs can react in similar but non-identical ways (JAMA2 experiments 
Chapter-3.1.1). Tumours can follow similar cellular adaptation profiles but often react 
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to drugs in dissimilar ways. It may be possible to try using small biopsies soon after 
treatment and even within the first 24 hours to see in which direction the tumour is 
adapting so as to tailor treatment, but predicting the outcome of the adaptation model 
can currently only be guess work which negates the rational for precise informed 
predictive sequential regimens. It may be useful to look at gene amplification or copy 
number alongside gene expression profiles, but the algorithms required to predict 
sensitivity from these data will be complex.  Nevertheless, it may be possible to use 
drugs in combination to target connecting pathways and prediction of these may be 
feasible. 
 
It should be remembered that not all resistance is acquired through adaptation. 
Consideration must also be given to the role of somatic selection. It is known that 
within the vast population of cells making up the tumour mass not all tumours contain 
identical mutations. This however, can become a problem when certain mutations 
have a survival advantage over neighbouring cells, allowing them to proliferate into an 
expanding clonal cluster of drug resistant cells. This situation can arise following 
therapeutic intervention where a selective pressure is placed on sensitive cells 
allowing resistant clones to continue to grow and invade (316, 317). 
 
Even though studies looking at single genes showed both similarities and significant 
differences related to sensitivity to chemotherapeutic agents in some cases the bigger 
picture can be easily overlooked. Those results that were excluded as outliers or 
seemed to contradict all other results may have found other means by which to act. 
Looking at single genes may suggest how these tumours will react to a given drug 
exposure, but as shown in these cellular adaptation profiles, profiling multiple genes 
can give more information as to the behaviour of the individual tumour. If we are to 
continue to improve therapies and regimens, strategies that are more individualised 
will be required. It has long been known that tumours of the same type are extremely 
heterogenic and through studying these cellular and gene expression profiles we can 
see their adaptation to chemotherapy is no exception. Repeated tests alongside 
treatment to show how the tumour is adapting and advancing can only help improve 
understanding of individual responses allowing a more direct and specific regime to be 
employed.  
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8.1.2 Multiple Molecular target Approach to Treatment  
Evidence presented here shows the importance of the tyrosine kinase receptors 
including EGFR, HER2/3 and IGFR1/2 as well as the importance of their signalling 
pathways through both RAS and PI3K/AKT in solid tumours. The cross-signalling 
involved with these pathways suggests a rationale for the deregulation of these 
signalling cascades via multiple modes of action. It has been shown that, highly 
selective or specific blocking of single sites involved in signaling pathways has been 
associated with limited or sporadic responses (318). Improved understanding of the 
complexity of signal transduction processes and their roles in cancer suggest a strategy 
for simultaneous inhibition of several key pathway positions to help optimize overall 
therapeutic benefit associated with preventing alternative mechanisms associated 
with bypassing pathway inhibition. 
8.1.3 Targeting Cellular Signalling through RAS  
Statins may influence ovarian cancer biology through disruption of Ras signalling by 
inhibiting the enzyme HMG-CoA reductase, halting the mevalonate pathway and thus 
RAS protein prenylation which is required for signalling. Active RAS signalling has been 
shown to occur in high-grade ovarian cancers, suggesting that the RAS pathway may be 
important in the maintenance rather than the establishment of tumour growth and 
metastasis (311, 319). By combining fluvastatin with another mevalonate pathway 
inhibitor zoledronic acid, sensitivity was increased showing a synergistic relationship 
with these agents in the ovarian tumours tested in this study. While this combination 
may in fact work by promoting accumulation of the cytotoxic by product ApppI, 
disruption of protein prenylation and farnesylation through the inhibition of the 
mevalonate pathway remains an attractive strategy. The zoledronic acid fluvastatin 
combination may still prove to be a useful combination for future applications in 
patients with ovarian cancer, and clinical trials are probably warranted as there are 
few maintenance options for patients with recurrent ovarian cancer.   
 
Platinum compounds such as cisplatin are still one of the most widely used classes of 
drugs for the treatment of ovarian cancer. The efficacy of these agents has been 
successfully augmented with many drugs such as paclitaxel to provide combination 
therapy which is used routinely as standard treatment.  
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Although extensive DNA damage from cisplatin treatment can induce cell death by 
apoptosis, several signalling pathways, including AKT and MAPKs, are known to 
regulate cisplatin induced apoptosis (53). Cisplatin combinations with MEK, PI3K and 
mTOR inhibitors in this study showed some increase in sensitivity compared with single 
agent activity. However, more interesting was that the activity of these targeted drug 
combinations could still be achieved when reduced concentrations of cisplatin were 
introduced. 
 
By combining platinum with molecular targeted therapy it may be possible to lower 
the dosage of cisplatin currently employed without losing sensitivity, which could help 
alleviate its side effects, which include nephrotoxicity and neurotoxicity. 
8.1.4 Targeting Cellular Signalling through EGFR  
Growth factor receptors are overexpressed and/or dysregulated in many ovarian 
tumours, with EGFR overexpression occurring regularly (320-324). Despite its 
overexpression, anti-EGFR treatments have had little success in ovarian cancer. In 
other cancers, EGFR-activating mutations are associated with enhanced sensitivity to 
EGFR inhibitors. However, these mutations are rare in ovarian cancer and are 
therefore not suitable predictive markers for this disease.  
 
In general, tyrosine kinase inhibitors (TKIs) have shown variable activity in solid 
tumours despite initial evidence for the key importance of the pathways they disrupt. 
The discovery that responsive subsets of these patients had activating mutations in 
relevant receptors initiated increased interest for these mutations as markers for 
sensitivity. In particular, lung cancers that harbour the EGFR kinase domain mutations 
show greater response to small molecule EGFR inhibitors such as gefitinib and 
erlotinib. Unfortunately, the activity seen with these inhibitors is limited as cancers 
invariably develop resistance mechanisms against these drugs (325). The most 
common mechanism of acquired resistance to the EGFR inhibitors gefitinib and 
erlotinib in lung cancer is the development of a secondary EGFR mutation, T790M 
which increases the affinity of the EGFR for ATP, thereby reducing the efficacy of these 
drugs (117).  
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Other EGFR inhibitor resistance mechanisms include the amplification of the MET 
oncogene. When MET is overexpressed it activates HER3 independently of EGFR (or 
HER2), and is able to maintain downstream signalling through both PI3K and ERK in the 
presence of gefitinib.  
 
There is increasing evidence to support the importance of the involvement of the 
upregulation of HER3 gene expression with its ability to increase the signalling 
potential of other HER family receptors (326, 327).  
 
This study has shown the importance of the interplay between HER family receptors 
and IGF1/2R. Sensitivity to EGFR inhibitors gefitinib and erlotinib is seen when 
increased expression of EGFR, HER2 and HER3 receptors combine with low levels of 
IGF1R and IGF2R receptors (Chapter 6 - . It may be interesting to investigate if the 
inverse relationship seen here with tyrosine kinase inhibitors occurs in other tumour 
types. These receptors may also prove useful as potential molecular markers for 
sensitivity to EGFR inhibitors in patients expressing this profile. The inhibition of IGF1R 
has shown to enhance response to HER targeted drug treatment in many solid 
tumours (328-331), so it is no wonder that many inhibitors of IGF1R are currently in 
phase I/II trials (332). 
 
Resistance to EGFR inhibitors by maintenance of PI3K signalling can also occur through 
activation of the IGF1R signalling pathway (261). The importance of the PI3K pathway 
as well as its re-activation associated with acquired resistance to TKIs in EGFR addicted 
cancers strengthens the support for use of PI3K inhibitors in multiple targeted 
treatment strategies. Results here show the potential of incorporating PI3K pathway 
inhibitors with EGFR target therapies for an effective strategy to overcome acquired 
resistance as well as the transactivation associated with these signalling pathways. 
Early safety and tolerability studies are already under way for solid tumours with the 
combination of PI3K inhibitors (XL765 and XL147, Exelixis, San Francisco, CA) and the 
EGFR inhibitor erlotinib (333, 334). 
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8.1.5 Targeted Treatment the Present and Future Strategies 
We are firmly in the midst of the molecularly targeted era of personalised oncology. 
Cancer patients can start to expect treatment regimes based more dominantly on their 
individual tumour’s signalling and molecular type rather than the empirical approach 
oncologists have previously seen to be successful in the past. This will inevitably 
require patients to have adequate amounts of diagnostic tissue for multiple 
histological and molecular techniques. With increased efficacy of early detection and 
tumour screening, in many tumour types the supply of viable diagnostic material is 
rapidly becoming inadequate. Novel methods, such as isolation of circulating DNA from 
blood will become vital for future diagnostic strategies (335-340). It will eventually 
require significant thought to future planning with regards to diagnostic services 
including close collaboration between all arms of cellular pathology, blood science, 
molecular pathology and cytogenetics (341). 
8.1.6 Future Work 
Collaborative work with the University of Strathclyde will continue based on the use of 
the automated 384 well based assay (ATP- THCA) methods, with the possibility of 
evaluating individual fractions of the compounds which were found sensitive. The 
checkerboard adaptation to this method is also currently in use for other drug 
combination evaluations for use in collaborative industry based projects. 
 
Studies identifying a possible benefit for combinational EGFR and PI3K targeted 
treatment is ongoing with future grant proposals being submitted by Prof. Cree based 
on work completed here. The aim is to extend these observations into possible clinical 
trials, all while monitoring the molecular mechanisms involved in patient response. 
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